
( (FRAG (NP (N Regulation)
            (PP (P of)
                (NP (NPR IL-6)
                    (N synthesis)
                    (PP (P in)
                        (NP (ADJ human)
                            (NML (ADJ peripheral)
                                 (N blood))
                            (NML (ADJ mononuclear)
                                 (NS cells))))))
            (PP (P by)
                (NP (NP (NPR C3a))
                    (CONJP (CONJ and)
                           (NP (NPR C3a_desArg))))))
        (. .))
  (ID 1_nonfiction_GENIA-1999;99101510,1;NE))

( (IP-MAT (NP-SBJ (PRN (D The)
                       (N anaphylatoxin))
                  (NPR C3a))
          (HVP has)
          (BEN been)
          (VAN reported)
          (IP-INF (TO to)
                  (HV have)
                  (NP-OB1 (ADJ immunomodulatory)
                          (NS effects)
                          (PP (P on)
                              (NP (D a)
                                  (N number)
                                  (PP (P of)
                                      (NP (ADJ different)
                                          (N cell)
                                          (NS types)))))))
          (. .))
  (ID 2_nonfiction_GENIA-1999;99101510,2;NE))

( (IP-MAT (PP (P In)
              (NP (D this)
                  (N study)))
          (NP-SBJ (PRO we))
          (VBD investigated)
          (NP-OB1 (D the)
                  (NS effects)
                  (PP (P of)
                      (NP (NP (NPR C3a))
                          (CONJP (CONJ and)
                                 (NP (NPR C3a_desArg)))))
                  (PP (P on)
                      (NP (NML (NP (N gene)
                                   (N expression))
                               (CONJP (CONJ and)
                                      (NP (N protein)
                                          (N secretion))))
                          (PP (P of)
                              (NP (NPR IL-6)))))
                  (PP (P in)
                      (NP (ADJ human)
                          (NS PBMCs))))
          (, ,)
          (ADJP-SPR (CONJ either)
                    (ADJP (ADJ alone))
                    (CONJP (CONJ or)
                           (ADJP (PP (P in)
                                     (NP (N combination)
                                         (PP (P with)
                                             (NP (NP (NPR LPS))
                                                 (CONJP (CONJ or)
                                                        (NP (NPR IL-1beta))))))))))
          (. .))
  (ID 3_nonfiction_GENIA-1999;99101510,3;NE))

( (IP-MAT (NP-SBJ (NP (NPR C3a))
                  (CONJP (CONJ or)
                         (NP (NPR C3a_desArg))))
          (FP alone)
          (VBD exhibited)
          (NP-OB1 (Q no)
                  (N effect)
                  (PP (P on)
                      (NP (D the)
                          (NML (NP (N expression))
                               (CONJP (CONJ or)
                                      (NP (N secretion))))
                          (PP (P of)
                              (NP (NPR IL-6))))))
          (. .))
  (ID 4_nonfiction_GENIA-1999;99101510,4;NE))

( (IP-MAT (ADVP (ADV However))
          (, ,)
          (PP (P when)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (NPR PBMC))
                              (BED were)
                              (VAN stimulated)
                              (PP (P with)
                                  (NP (NP (NPR LPS))
                                      (CONJP (CONJ or)
                                             (NP (NPR IL-1beta))))))))
          (CND *)
          (, ,)
          (NP-SBJ (BIND *group*)
                  (Q both)
                  (NML (NP (NPR C3a))
                       (CONJP (CONJ and)
                              (NP (NPR C3a_desArg)))))
          (BED were)
          (VAN found)
          (IP-INF (TO to)
                  (VB enhance)
                  (NP-OB1 (NPR IL-6)
                          (N release)
                          (PP (P by)
                              (NP (NPR PBMC))))
                  (PP (P in)
                      (NP (D a)
                          (ADJ dose-dependent)
                          (N manner))))
          (. .))
  (ID 5_nonfiction_GENIA-1999;99101510,5;NE))

( (IP-MAT (PP (P Since)
              (CP-ADV (C 0)
                      (IP-SUB (IP-SUB (NP-SBJ (NPR C3a))
                                      (HVP has)
                                      (BEN been)
                                      (VAN shown)
                                      (IP-INF (TO to)
                                              (VB induce)
                                              (NP-OB1 (NPR PGE2)
                                                      (N production)))
                                      (PP (P by)
                                          (NP (NS monocytes))))
                              (, ,)
                              (CONJP (CONJ and)
                                     (IP-SUB (NP-SBJ (NPR PGE2))
                                             (HVP has)
                                             (BEN been)
                                             (VAN shown)
                                             (IP-INF (TO to)
                                                     (VB influence)
                                                     (NP-OB1 (NPR cytokine)
                                                             (N production))))))))
          (, ,)
          (NP-SBJ (PRO we))
          (VBD investigated)
          (NP-OB1 (D the)
                  (ADJ potential)
                  (N role)
                  (PP (P of)
                      (NP (NPR PGE2)))
                  (PP (P in)
                      (NP (ADJP (ADJ C3a-mediated))
                          (N enhancement)
                          (PP (P of)
                              (IP-ABS (NP-SBJ (NP (NPR LPS-))
                                              (CONJP (CONJ and)
                                                     (NP (NPR IL-1beta-))))
                                      (VBN induced)
                                      (NP-OB1 (NPR IL-6)
                                              (N production)))))))
          (. .))
  (ID 6_nonfiction_GENIA-1999;99101510,6;NE))

( (IP-MAT (NP-SBJ (NPR Indomethacin))
          (VP (VP (VBD blocked)
                  (NP-OB1 (NPR PGE2)
                          (N release)))
              (, ,)
              (CONJP (CONJ but)
                     (VP (HVD had)
                         (NP-OB1 (Q no)
                                 (N influence)
                                 (PP (P on)
                                     (NP (D the)
                                         (VBN observed)
                                         (NS effects)
                                         (PP (P of)
                                             (NP (NPR C3a)))))))))
          (, ,)
          (IP-PPL (VAG suggesting)
                  (CP-THT (C that)
                          (IP-SUB (NP-SBJ (D the)
                                          (NS effects)
                                          (PP (P of)
                                              (NP (NPR C3a)))
                                          (PP (P on)
                                              (NP (NPR IL-6)
                                                  (N production))))
                                  (BEP are)
                                  (ADJP (ADJ independent)
                                        (PP (P of)
                                            (NP (NPR PGE2)
                                                (N formation)
                                                (PP (P by)
                                                    (NP (NS monocytes)))))))))
          (. .))
  (ID 7_nonfiction_GENIA-1999;99101510,7;NE))

( (IP-MAT (NP-SBJ (NPR Northern)
                  (NPR blot)
                  (N analysis))
          (VBD showed)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NP (NPR C3a))
                                  (CONJP (CONJ (ADVR as)
                                               (ADV well)
                                               (P as))
                                         (NP (NPR C3a_desArg))))
                          (VBD enhanced)
                          (NP-OB1 (ADJP (ADJ LPS-induced))
                                  (NPR mRNA)
                                  (NS levels))
                          (PP (P for)
                              (NP (NPR IL-6)))))
          (. .))
  (ID 8_nonfiction_GENIA-1999;99101510,8;NE))

( (IP-MAT (NP-SBJ (N Pretreatment)
                  (PP (P of)
                      (NP (NS PBMCs)
                          (PP (P with)
                              (NP (NPR pertussis)
                                  (N toxin))))))
          (VBD blocked)
          (NP-OB1 (D the)
                  (NS functions)
                  (PP (P of)
                      (NP (NP (NPR C3a))
                          (CONJP (CONJ and)
                                 (NP (NPR C3a_desArg))))))
          (, ,)
          (IP-PPL (VAG indicating)
                  (CP-THT (C that)
                          (IP-SUB (NP-SBJ (D the)
                                          (NS actions)
                                          (PP (P of)
                                              (NP (D these)
                                                  (NUM two)
                                                  (NS molecules))))
                                  (BEP are)
                                  (VAN mediated)
                                  (PP (P by)
                                      (NP (D a)
                                          (ADJP (NP (NPR G))
                                                (ADJ protein-coupled))
                                          (N pathway)))
                                  (NP-LGS *by*))))
          (. .))
  (ID 9_nonfiction_GENIA-1999;99101510,9;NE))

( (IP-MAT (ADVP (ADV Furthermore))
          (, ,)
          (NP-SBJ (PRO we))
          (VBD investigated)
          (NP-OB1 (D the)
                  (NS effects)
                  (PP (P of)
                      (NP (NP (NPR C3a))
                          (CONJP (CONJ and)
                                 (NP (NPR C3a_desArg)))))
                  (PP (P on)
                      (NP (NP (N induction)
                              (PP (P of)
                                  (NP (NPR NF-kappaB))))
                          (CONJP (CONJ and)
                                 (NP (RRC (VAG activating)
                                          (NP-OB1 (NPR protein-1)
                                                  (N binding))))))))
          (. .))
  (ID 10_nonfiction_GENIA-1999;99101510,10;NE))

( (IP-MAT (NP-SBJ (Q Both)
                  (NS molecules))
          (VBD enhanced)
          (NP-OB1 (NP (ADJP (ADJ LPS-induced))
                      (NPR NF-kappaB))
                  (CONJP (CONJ and)
                         (NP (RRC (VAG activating)
                                  (NP-OB1 (NPR protein-1)
                                          (N binding)
                                          (N activity))))))
          (. .))
  (ID 11_nonfiction_GENIA-1999;99101510,11;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS results))
          (VBP demonstrate)
          (NP-OB1 (D the)
                  (N capacity)
                  (PP (P of)
                      (NP (NP (ADJ intact)
                              (NPR C3a))
                          (CONJP (CONJ and)
                                 (NP (NP-POS (PRO its))
                                     (ADJ circulating)
                                     (N des-Arg)
                                     (N form)))))
                  (IP-INF (TO to)
                          (VB exert)
                          (NP-OB1 (ADJ immunmodulatory)
                                  (NS effects))
                          (ADVP (FW in)
                                (FW vitro))))
          (. .))
  (ID 12_nonfiction_GENIA-1999;99101510,12;NE))

( (FRAG (NP (N Comparison)
            (PP (P of)
                (NP (ADJ primary)
                    (N sensitization)
                    (PP (P of)
                        (NP (ADJ naive)
                            (NML (ADJ human)
                                 (NPR T)
                                 (NS cells))))
                    (PP (P to)
                        (NP (NPR varicella-zoster)
                            (N virus)
                            (NS peptides)))
                    (PP (P by)
                        (NP (ADJ dendritic)
                            (NS cells)))
                    (ADJP (FW in)
                          (FW vitro))))
            (PP (P with)
                (NP (NS responses)
                    (RRC (VBN elicited)
                         (ADVP (FW in)
                               (FW vivo))
                         (PP (P by)
                             (NP (NPR varicella)
                                 (N vaccination)))))))
        (. .))
  (ID 13_nonfiction_GENIA-1999;99101524,1;NE))

( (IP-MAT (NP-SBJ (ADJ Dendritic)
                  (NS cells)
                  (PRN (-LRB- -LRB-)
                       (NPR DC)
                       (-RRB- -RRB-)))
          (BEP are)
          (NP-OB1 (ADJ potent)
                  (N APC))
          (PP (P during)
              (NP (NP (ADJ primary))
                  (CONJP (CONJ and)
                         (NP (ADJ secondary)
                             (ADJ immune)
                             (COPY *)
                             (NS responses)
                             (COPY *)))))
          (. .))
  (ID 14_nonfiction_GENIA-1999;99101524,2;NE))

( (IP-MAT (NP-SBJ (D The)
                  (ADJ first)
                  (N objective)
                  (PP (P of)
                      (NP (D this)
                          (N study))))
          (BED was)
          (IP-INF (TO to)
                  (VB determine)
                  (CP-QUE (WQ whether)
                          (C 0)
                          (IP-SUB (NP-SBJ (ADJ human)
                                          (NS DC))
                                  (VBP mediate)
                                  (NP-OB1 (ADJP (FW in)
                                                (FW vitro))
                                          (N sensitization)
                                          (PP (P of)
                                              (NP (NPR naive)
                                                  (NPR CD4+)
                                                  (NPR T)
                                                  (NS cells)))
                                          (PP (P to)
                                              (NP (NS epitopes)
                                                  (PP (P of)
                                                      (NP (D the)
                                                          (ADJP (ADJ immediate)
                                                                (ADJ early))
                                                          (N 62)
                                                          (PRN (-LRB- -LRB-)
                                                               (NPR IE62)
                                                               (-RRB- -RRB-))
                                                          (N protein)
                                                          (PP (P of)
                                                              (NP (NPR varicella)
                                                                  (NPR zoster)
                                                                  (N virus)
                                                                  (PRN (-LRB- -LRB-)
                                                                       (NPR VZV)
                                                                       (-RRB- -RRB-))))))))))))
          (. .))
  (ID 15_nonfiction_GENIA-1999;99101524,3;NE))

( (IP-MAT (NP-SBJ (D The)
                  (N induction)
                  (PP (P of)
                      (NP (NPR CD4+)
                          (NPR T)
                          (N cell)
                          (ADJ proliferative)
                          (NS responses)
                          (PP (P to)
                              (NP (NUM eight)
                                  (ADJ synthetic)
                                  (NS peptides)
                                  (RRC (VAG representing)
                                       (NP-OB1 (N amino)
                                               (N acid)
                                               (NS sequences)
                                               (PP (P of)
                                                   (NP (D the)
                                                       (NPR VZV)
                                                       (N IE62)
                                                       (N protein))))))))))
          (BED was)
          (VAN assessed)
          (IP-PPL (VAG using)
                  (NP-OB1 (NML (NP (NPR T)
                                   (NS cells))
                               (CONJP (CONJ and)
                                      (NP (NS DC))))
                          (PP (P from)
                              (NP (ADJP (ADJ VZV-susceptible))
                                  (NS donors)))))
          (. .))
  (ID 16_nonfiction_GENIA-1999;99101524,4;NE))

( (IP-MAT (NP-SBJ (D The)
                  (ADJ second)
                  (N objective))
          (BED was)
          (IP-INF (TO to)
                  (VB compare)
                  (NP-OB1 (ADJP (FW in)
                                (FW vitro))
                          (NS responses)
                          (PP (P of)
                              (NP (ADJ naive)
                                  (NPR T)
                                  (NS cells))))
                  (PP (P with)
                      (NP (NS responses)
                          (PP (P to)
                              (NP (NPR VZV)
                                  (NS peptides)))
                          (RRC (VBN induced)
                               (ADVP (FW in)
                                     (FW vivo))
                               (PP (P after)
                                   (NP (N immunization)
                                       (PP (P with)
                                           (NP (NPR varicella)
                                               (N vaccine)))))))))
          (. .))
  (ID 17_nonfiction_GENIA-1999;99101524,5;NE))

( (IP-MAT (NP-SBJ (NPR T)
                  (N cell)
                  (N proliferation))
          (BED was)
          (VAN induced)
          (PP (P by)
              (NP (NUM three)
                  (NS peptides)
                  (, ,)
                  (PRN (NP (NP (NPR P1))
                           (, ,)
                           (CONJP (NP (NPR P4)))
                           (, ,)
                           (CONJP (CONJ and)
                                  (NP (NPR P7)))))))
          (, ,)
          (PP (P in)
              (NP (NUM 71-100)
                  (N %)
                  (PP (P of)
                      (NP (D the)
                          (NS donors)
                          (RRC (VAN tested)
                               (PP (PP (P before))
                                   (CONJP (CONJ and)
                                          (PP (P after)))
                                   (NP (N vaccination)
                                       (RRC (VAG using)
                                            (NP-OB1 (N DC))
                                            (PP (P as)
                                                (NP (N APC)))))))))))
          (. .))
  (ID 18_nonfiction_GENIA-1999;99101524,6;NE))

( (IP-MAT (NP-SBJ (NS Monocytes))
          (BED were)
          (NP-OB1 (ADJ effective)
                  (N APC))
          (PP (P for)
              (NP (NPR VZV)
                  (NS peptides)))
          (PP (FP only)
              (P after)
              (NP (N immunization)))
          (. .))
  (ID 19_nonfiction_GENIA-1999;99101524,7;NE))

( (IP-MAT (NP-SBJ (NUM Two)
                  (NS peptides)
                  (, ,)
                  (PRN (NP (NP (NPR P2))
                           (CONJP (CONJ and)
                                  (NP (NPR P8))))))
          (, ,)
          (VP (VP (VBD induced)
                  (NP-OB1 (ADJ naive)
                          (NPR T)
                          (N cell)
                          (N proliferation))
                  (ADVP (QR less)
                        (ADV effectively)))
              (CONJP (CONJ and)
                     (VP (BED were)
                         (ADVP (ADV also))
                         (ADJP (QR less)
                               (ADJ immunogenic)
                               (PP (P for)
                                   (NP (NPR T)
                                       (NS cells)
                                       (PP (P from)
                                           (NP (NP (VBN vaccinated))
                                               (CONJP (CONJ or)
                                                      (NP (ADJP (ADV naturally)
                                                                (ADJ immune))
                                                          (NS donors)
                                                          (COPY *)))))))))))
          (. .))
  (ID 20_nonfiction_GENIA-1999;99101524,8;NE))

( (IP-MAT (NP-SBJ (NPR T)
                  (N cell)
                  (N recognition)
                  (PP (P of)
                      (NP (ADJ specific)
                          (NS peptides))))
          (BED was)
          (ADJP (ADJ concordant)
                (PP (P between)
                    (NP (NP (ADJ naive)
                            (, ,)
                            (ADJ DC-mediated)
                            (NS responses))
                        (, ,)
                        (CONJP (CONJ and)
                               (NP (ADJ postvaccine)
                                   (NS responses))))))
          (IP-PPL (VAG using)
                  (NP-OB1 (NS monocytes))
                  (PP (P as)
                      (NP (N APC)))
                  (PP (P in)
                      (NP (NUM 69)
                          (N %)
                          (PP (P of)
                              (NP (NS comparisons)))
                          (-LRB- -LRB-)
                          (CODE (FW p)
                                (FW =)
                                (FW 0.05)
                                (, ;)
                                (FW chi2))
                          (-RRB- -RRB-))))
          (. ;))
  (ID 21_nonfiction_GENIA-1999;99101524,9;NE))

( (IP-MAT (NP-SBJ (D the)
                  (ADJ predictive)
                  (N value)
                  (PP (P of)
                      (NP (D a)
                          (ADJ positive)
                          (N response)
                          (PP (P to)
                              (NP (D an)
                                  (NPR IE62)
                                  (N peptide)))
                          (PP (P before)
                              (NP (N immunization)))
                          (PP (P for)
                              (NP (NPR T)
                                  (N cell)
                                  (N sensitization)
                                  (ADJP (FW in)
                                        (FW vivo)))))))
          (BED was)
          (NP-OB1 (NUM 82)
                  (N %))
          (. .))
  (ID 22_nonfiction_GENIA-1999;99101524,9;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS observations))
          (VBP indicate)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (ADJ primary)
                                  (NPR T)
                                  (N cell)
                                  (NS responses)
                                  (RRC (VBN detected)
                                       (ADVP (FW in)
                                             (FW vitro))
                                       (VAG using)
                                       (NP-OB1 (NS DC))
                                       (PP (P as)
                                           (NP (N APC)))))
                          (MD may)
                          (BE be)
                          (ADJP (ADJ useful)
                                (IP-INF (TO to)
                                        (VB characterize)
                                        (NP-OB1 (D the)
                                                (ADJ potential)
                                                (N immunogenicity)
                                                (PP (P of)
                                                    (NP (ADJ viral)
                                                        (N protein)
                                                        (NS epitopes)))
                                                (ADJP (FW in)
                                                      (FW vivo)))))))
          (. .))
  (ID 23_nonfiction_GENIA-1999;99101524,10;NE))

( (IP-MAT (NP-SBJ (ADJP (ADV Mildly)
                        (ADJ oxidized))
                  (ADJ low-density)
                  (NS lipoproteins))
          (VBP decrease)
          (NP-OB1 (NP (ADJ early)
                      (N production)
                      (PP (P of)
                          (NP (NPR interleukin)
                              (NPR 2))))
                  (CONJP (CONJ and)
                         (NP (ADJ nuclear)
                             (N factor)
                             (N kappaB)
                             (N binding)
                             (PP (P to)
                                 (NP (N DNA)))
                             (PP (P in)
                                 (NP (ADJ activated)
                                     (NS T-lymphocytes))))))
          (. .))
  (ID 24_nonfiction_GENIA-1999;99102085,1;NE))

( (IP-MAT (NP-SBJ (VBN Activated)
                  (NS T-lymphocytes))
          (BEP are)
          (VAN found)
          (ADVP-TMP (ADV early))
          (PP (P in)
              (NP (N atherosclerosis)
                  (NS lesions)))
          (, ,))
  (ID 25_nonfiction_GENIA-1999;99102085,2;NE))

( (IP-MAT (CONJ but)
          (NP-SBJ (Q little))
          (BEP is)
          (VAN known)
          (PP (P about)
              (NP (NP-POS (PRO their))
                  (N role)))
          (. .))
  (ID 26_nonfiction_GENIA-1999;99102085,2;NE))

( (IP-MAT (NP-SBJ (VBN Oxidized)
                  (ADJ low-density)
                  (NS lipoproteins)
                  (PRN (-LRB- -LRB-)
                       (NS oxLDLs)
                       (-RRB- -RRB-)))
          (BEP are)
          (VAN considered)
          (IP-INF (TO to)
                  (BE be)
                  (VAN involved)
                  (PP (P in)
                      (NP (D the)
                          (N pathogenesis)
                          (PP (P of)
                              (NP (D the)
                                  (NS lesions))))))
          (, ,))
  (ID 27_nonfiction_GENIA-1999;99102085,3;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (PRO we))
          (HVP have)
          (ADVP-TMP (ADV previously))
          (VBN demonstrated)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NS oxLDLs))
                          (VBP inhibit)
                          (NP-OB1 (NP (NEG not)
                                      (FP only)
                                      (N interleukin)
                                      (PRN (-LRB- -LRB-)
                                           (N IL)
                                           (-RRB- -RRB-))
                                      (N -2)
                                      (N -receptor)
                                      (N expression)
                                      (PP (P on)
                                          (NP (D the)
                                              (N surface)
                                              (PP (P of)
                                                  (NP (ADJP (FW in)
                                                            (ADJ vitro-activated))
                                                      (NS T-lymphocytes))))))
                                  (CONJP (CONJ but)
                                         (ADV also)
                                         (NP (NP-POS (PRO their))
                                             (N proliferation))))))
          (. .))
  (ID 28_nonfiction_GENIA-1999;99102085,3;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (HVP have)
          (ADVP-TMP (ADV now))
          (VBN investigated)
          (NP-OB1 (D the)
                  (N effect)
                  (PP (P of)
                      (NP (NS oxLDLs)))
                  (PP (PP (P on)
                          (NP (N blast)
                              (N differentiation)))
                      (, ,)
                      (CONJP (PP (P on)
                                 (NP (NPR IL-2)
                                     (N synthesis))))
                      (CONJP (CONJ and)
                             (PP (P on)
                                 (NP (D the)
                                     (N activation)
                                     (PP (P of)
                                         (NP (D the)
                                             (ADJ nuclear)
                                             (N factor)
                                             (N kappaB)
                                             (PRN (-LRB- -LRB-)
                                                  (NPR NF-kappaB)
                                                  (-RRB- -RRB-))
                                             (N system)))
                                     (PP (P in)
                                         (NP (ADJ activated)
                                             (NS lymphocytes))))))))
          (. .))
  (ID 29_nonfiction_GENIA-1999;99102085,4;NE))

( (IP-MAT (NP-SBJ (ADV Mildly)
                  (NS oxLDLs)
                  (PRN (-LRB- -LRB-)
                       (NUMP (NUM 50)
                             (CONJ and)
                             (NUM 100))
                       (N microgram/ml)
                       (-RRB- -RRB-)))
          (VBD decreased)
          (NP-OB1 (NP (D the)
                      (N number)
                      (PP (P of)
                          (NP (NS lymphoblasts))))
                  (CONJP (CONJ and)
                         (NP (D the)
                             (N level)
                             (PP (P of)
                                 (NP (NPR IL-2)
                                     (N concentration))))))
          (PP (P in)
              (NP (D the)
                  (N culture)
                  (NS supernatants)))
          (PP (P after)
              (NP (N activation)
                  (PP (P of)
                      (NP (NS lymphocytes)))
                  (PP (P by)
                      (NP (NP (NPR phytohaemagglutinin))
                          (CONJP (CONJ and)
                                 (NP (NPR PMA+ionomycin)))))))
          (. .))
  (ID 30_nonfiction_GENIA-1999;99102085,5;NE))

( (IP-MAT (NP-SBJ (D The)
                  (N inhibition)
                  (PP (P of)
                      (NP (NPR IL-2)
                          (N production))))
          (BED was)
          (VAN observed)
          (PP (P in)
              (NP (D the)
                  (NPR CD3)
                  (N T-lymphocyte)
                  (N cytoplasm)))
          (ADVP-TMP (ADVR as)
                    (ADV early)
                    (PP (P as)
                        (NP (NUM 4)
                            (N h)
                            (PP (P after)
                                (NP (N activation)
                                    (PP (P by)
                                        (NP (NPR PMA+ionomycin))))))))
          (. .))
  (ID 31_nonfiction_GENIA-1999;99102085,6;NE))

( (IP-MAT (NP-SBJ (D The)
                  (N study)
                  (PP (P of)
                      (NP (NPR NF-kappaB))))
          (VBD showed)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NS oxLDLs))
                          (VBD led)
                          (PP (P to)
                              (NP (D a)
                                  (N decrease)
                                  (PP (P of)
                                      (NP (ADJ activation-induced)
                                          (NPR p65/p50)
                                          (NPR NF-kappaB)
                                          (N heterodimer)
                                          (N binding)
                                          (PP (P to)
                                              (NP (N DNA)))))))
                          (, ,)
                          (PP (P whereas)
                              (CP-ADV (C 0)
                                      (IP-SUB (NP-SBJ (D the)
                                                      (N presence)
                                                      (PP (P of)
                                                          (NP (D the)
                                                              (ADJ constitutive)
                                                              (ADJ nuclear)
                                                              (N form)
                                                              (PP (P of)
                                                                  (NP (N p50)
                                                                      (N dimer))))))
                                              (BED was)
                                              (ADJP (ADJ unchanged)))))))
          (. .))
  (ID 32_nonfiction_GENIA-1999;99102085,7;NE))

( (IP-MAT (NP-SBJ (D This))
          (BED was)
          (VBN correlated)
          (PP (P with)
              (NP (D an)
                  (ADJ unchanged)
                  (N level)
                  (PP (P of)
                      (NP (D the)
                          (ADJ active)
                          (N form)
                          (PP (P of)
                              (NP (PRN (D the)
                                       (ADJ cytosolic)
                                       (N inhibitor)
                                       (N protein))
                                  (NPR IkappaB-alpha)))))))
          (. .))
  (ID 33_nonfiction_GENIA-1999;99102085,8;NE))

( (IP-MAT (IP-PPL (VBN Taken)
                  (ADVP (ADV together)))
          (, ,)
          (NP-SBJ (D these)
                  (NS observations))
          (VBP suggest)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D the)
                                  (ADJ immunosuppressive)
                                  (N effect)
                                  (PP (P of)
                                      (NP (NS oxLDLs))))
                          (MD might)
                          (VB operate)
                          (PP (P via)
                              (NP (D a)
                                  (N dysregulation)
                                  (PP (P of)
                                      (NP (D the)
                                          (N T-lymphocyte)
                                          (N activation)
                                          (NS mechanisms)))))))
          (. .))
  (ID 34_nonfiction_GENIA-1999;99102085,9;NE))

( (IP-MAT (NP-SBJ (D The)
                  (N activity)
                  (PP (P of)
                      (NP (PRN (D the)
                               (NPR CCAAT)
                               (N -box)
                               (N binding)
                               (N factor))
                          (NPR NF-Y))))
          (BEP is)
          (VAN modulated)
          (PP (P through)
              (NP (D the)
                  (VBN regulated)
                  (N expression)
                  (PP (P of)
                      (NP (NP-POS (PRO its))
                          (NPR A)
                          (N subunit)))))
          (PP (P during)
              (NP (N monocyte)))
          (PP (P to)
              (NP (N macrophage)
                  (N differentiation)))
          (, :))
  (ID 35_nonfiction_GENIA-1999;99102381,1;NE))

( (FRAG (NP (N regulation)
            (PP (P of)
                (NP (ADJ tissue-specific)
                    (NS genes)))
            (PP (P through)
                (NP (D a)
                    (ADJ ubiquitous)
                    (N transcription)
                    (N factor))))
        (. .))
  (ID 36_nonfiction_GENIA-1999;99102381,1;NE))

( (IP-MAT (PP (P In)
              (NP (D this)
                  (N study)))
          (, ,)
          (NP-SBJ (PRO we))
          (VBD analyzed)
          (NP-OB1 (D the)
                  (N regulation)
                  (PP (P of)
                      (NP (NPR NF-Y)
                          (N expression)))
                  (PP (P during)
                      (NP (ADJ human)
                          (N monocyte)
                          (PP (P to)
                              (NP (N macrophage)
                                  (N maturation))))))
          (. .))
  (ID 37_nonfiction_GENIA-1999;99102381,2;NE))

( (IP-MAT (NP-SBJ (NPR NF-Y))
          (BEP is)
          (NP-OB1 (D a)
                  (ADJP (ADJP (ADJ ubiquitous))
                        (CONJP (CONJ and)
                               (ADJP (ADV evolutionarily)
                                     (ADJ conserved))))
                  (N transcription)
                  (N factor)
                  (CP-REL (WNP-1 0)
                          (C that)
                          (IP-SUB (NP-SBJ *T*-1)
                                  (VBP binds)
                                  (ADVP (ADV specifically))
                                  (PP (P to)
                                      (NP (D the)
                                          (NPR CCAAT)
                                          (N motif)
                                          (ADJP (ADJ present)
                                                (PP (P in)
                                                    (NP (D the)
                                                        (ADJ 5')
                                                        (N promoter)
                                                        (N region)
                                                        (PP (P of)
                                                            (NP (D a)
                                                                (ADJ wide)
                                                                (N variety)
                                                                (PP (P of)
                                                                    (NP (NS genes)))))))))))))
          (. .))
  (ID 38_nonfiction_GENIA-1999;99102381,3;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBP show)
          (ADVP-LOC (ADV here))
          (CP-THT (C that)
                  (IP-SUB (PP (P in)
                              (NP (ADJ circulating)
                                  (NS monocytes)))
                          (, ,)
                          (NP-SBJ (NPR NF-Y)
                                  (N binding)
                                  (N activity))
                          (BEP is)
                          (NEG not)
                          (VAN detected)
                          (PP (P on)
                              (NP (D the)
                                  (NPR CCAAT)
                                  (N motif)
                                  (ADJP (ADJ present)
                                        (PP (P in)
                                            (NP (D the)
                                                (NS promoters)
                                                (PP (P of)
                                                    (NP (NS genes)))
                                                (ADJP (ADJ such)
                                                      (PP (P as)
                                                          (NP (NP (ADJ major)
                                                                  (N histocompatibility)
                                                                  (N complex)
                                                                  (PRN (-LRB- -LRB-)
                                                                       (N MHC)
                                                                       (-RRB- -RRB-))
                                                                  (N class)
                                                                  (N II))
                                                              (, ,)
                                                              (CONJP (NP (NPR gp91-phox)))
                                                              (, ,)
                                                              (CONJP (NP (NPR mig)))
                                                              (, ,)
                                                              (CONJP (CONJ and)
                                                                     (NP (NPR fibronectin))))))))))))
                  (, ,)
                  (PP (P whereas)
                      (CP-ADV (C 0)
                              (IP-SUB (PP (P during)
                                          (NP (N macrophage)
                                              (N differentiation)))
                                      (, ,)
                                      (NP-SBJ (D a)
                                              (ADJ progressive)
                                              (N increase)
                                              (PP (P in)
                                                  (NP (NPR NF-Y)
                                                      (N binding)
                                                      (N activity))))
                                      (BEP is)
                                      (VAN observed)
                                      (PP (P on)
                                          (NP (D these)
                                              (NS promoters)))))))
          (. .))
  (ID 39_nonfiction_GENIA-1999;99102381,4;NE))

( (IP-MAT (NP-SBJ (N Analysis)
                  (PP (P of)
                      (NP (NPR NF-Y)
                          (N subunit)
                          (N expression))))
          (VBP indicates)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D the)
                                  (N absence)
                                  (PP (P of)
                                      (NP (NPR NF-Y)
                                          (N activity)
                                          (PP (P in)
                                              (NP (ADJ circulating)
                                                  (NS monocytes))))))
                          (BEP is)
                          (VAN caused)
                          (PP (P by)
                              (NP (D a)
                                  (N lack)
                                  (PP (P of)
                                      (NP (D the)
                                          (NPR A)
                                          (N subunit)))))
                          (NP-LGS *by*)))
          (. .))
  (ID 40_nonfiction_GENIA-1999;99102381,5;NE))

( (IP-MAT (ADVP (ADV Furthermore))
          (, ,)
          (NP-SBJ (N addition)
                  (PP (P of)
                      (NP (D the)
                          (ADJ recombinant)
                          (NPR NF-YA)
                          (N subunit))))
          (VBP restores)
          (NP-OB1 (NPR NF-Y)
                  (N binding))
          (. .))
  (ID 41_nonfiction_GENIA-1999;99102381,6;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D the)
                                  (N lack)
                                  (PP (P of)
                                      (NP (NPR NF-YA)
                                          (N protein))))
                          (BEP is)
                          (ADJP (ADJ due)
                                (PP (PP (P to)
                                        (NP (ADJ posttranscriptional)
                                            (N regulation)))
                                    (CONJP (CONJ and)
                                           (PP (NEG not)
                                               (P to)
                                               (NP (D a)
                                                   (ADJ specific)
                                                   (ADJ proteolytic)
                                                   (N activity))))))))
          (. .))
  (ID 42_nonfiction_GENIA-1999;99102381,7;NE))

( (IP-MAT (PP (P In)
              (NP (N fact)))
          (, ,)
          (NP-SBJ (NPR NF-YA)
                  (N mRNA))
          (BEP is)
          (ADJP (ADJ present)
                (PP (P at)
                    (NP (D the)
                        (ADJ same)
                        (N level)))
                (PP (P at)
                    (NP (Q all)
                        (NS days)
                        (PP (P of)
                            (NP (N monocyte)
                                (N cultivation))))))
          (, ,)
          (PP (P whereas)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (D the)
                                      (N protein))
                              (VP (VP (BEP is)
                                      (ADJP (ADJ absent)
                                            (PP (P in)
                                                (NP (ADV freshly)
                                                    (VBN isolated)
                                                    (NS monocytes)))))
                                  (CONJP (CONJ but)
                                         (VP (BEP is)
                                             (ADVP (ADV progressively))
                                             (VBN synthesized)
                                             (PP (P during)
                                                 (NP (D the)
                                                     (N maturation)
                                                     (N process)))))))))
          (. .))
  (ID 43_nonfiction_GENIA-1999;99102381,8;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (ADVP (ADV thus))
          (VBP conclude)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D the)
                                  (NPR NF-YA)
                                  (N subunit))
                          (VBP plays)
                          (NP-OB1 (D a)
                                  (ADJ relevant)
                                  (N role)
                                  (PP (P in)
                                      (IP-PPL (VAG activating)
                                              (NP-OB1 (N transcription)
                                                      (PP (P of)
                                                          (NP (NS genes)
                                                              (ADJP (ADV highly)
                                                                    (VBN expressed)
                                                                    (PP (P in)
                                                                        (NP (ADJ mature)
                                                                            (NS monocytes))))))))))))
          (. .))
  (ID 44_nonfiction_GENIA-1999;99102381,9;NE))

( (IP-MAT (PP (P In)
              (NP (N line)
                  (PP (P with)
                      (NP (D this)
                          (N conclusion)))))
          (, ,)
          (NP-SBJ (PRO we))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D the)
                                  (N cut/CDP)
                                  (N protein)
                                  (, ,)
                                  (PRN (D a)
                                       (ADJ transcriptional)
                                       (N repressor)
                                       (CP-REL (WNP-1 0)
                                               (C that)
                                               (IP-SUB (NP-SBJ *T*-1)
                                                       (VBP inhibits)
                                                       (NP-OB1 (NPR gpc91-phox)
                                                               (N gene)
                                                               (N expression))
                                                       (PP (P by)
                                                           (IP-PPL (VAG preventing)
                                                                   (NP-OB1 (NPR NF-Y)
                                                                           (N binding)
                                                                           (PP (P to)
                                                                               (NP (D the)
                                                                                   (N CAAT)
                                                                                   (N box))))))
                                                       (CRD *)))))
                          (, ,)
                          (BEP is)
                          (ADJP (ADJ absent)
                                (PP (P in)
                                    (NP (NS monocytes))))))
          (. .))
  (ID 45_nonfiction_GENIA-1999;99102381,10;NE))

( (IP-MAT (VAG Accessing)
          (NP-OB1 (NPR Epstein-Barr)
                  (ADJ virus-specific)
                  (N T-cell)
                  (N memory))
          (PP (P with)
              (NP (ADJ peptide-loaded)
                  (ADJ dendritic)
                  (NS cells)))
          (. .))
  (ID 46_nonfiction_GENIA-1999;99102590,1;NE))

( (IP-MAT (NP-SBJ (D The)
                  (ADJ conventional)
                  (NS means)
                  (PP (P of)
                      (IP-PPL (VAG studying)
                              (NP-OB1 (ADJP (NP (NPR Epstein-Barr)
                                                (N virus)
                                                (PRN (-LRB- -LRB-)
                                                     (N EBV)
                                                     (-RRB- -RRB-)))
                                            (ADJ -induced))
                                      (ADJ cytotoxic)
                                      (N T-lymphocyte)
                                      (PRN (-LRB- -LRB-)
                                           (N CTL)
                                           (-RRB- -RRB-))
                                      (N memory))
                              (, ,)
                              (PP (P by)
                                  (NP (ADJP (FW in)
                                            (FW vitro))
                                      (N stimulation)
                                      (PP (P with)
                                          (NP (D the)
                                              (ADJP (ADV latently)
                                                    (ADJ infected))
                                              (N autologous)
                                              (N lymphoblastoid)
                                              (N cell)
                                              (N line)
                                              (PRN (-LRB- -LRB-)
                                                   (N LCL)
                                                   (-RRB- -RRB-)))))))))
          (, ,)
          (HVP has)
          (NP-OB1 (ADJ important)
                  (NS limitations))
          (. .))
  (ID 47_nonfiction_GENIA-1999;99102590,2;NE))

( (IP-MAT (ADVP-TMP (ADV First))
          (, ,)
          (NP-SBJ (PRO it))
          (VBP gives)
          (NP-OB1 (Q no)
                  (N information)
                  (PP (P on)
                      (NP (N memory))))
          (PP (P to)
              (NP (ADJ lytic)
                  (N cycle)
                  (NS antigens)))
          (NP-OB2 *to*)
          (. ;))
  (ID 48_nonfiction_GENIA-1999;99102590,3;NE))

( (IP-MAT (ADVP (ADJ second))
          (, ,)
          (NP-SBJ (PRO it))
          (ADVP (ADV preferentially))
          (VBP amplifies)
          (NP-OB1 (D the)
                  (ADJ dominant)
                  (NS components)
                  (PP (P of)
                      (NP (ADJ latent)
                          (ADJ antigen-specific)
                          (N memory))))
          (PP (P at)
              (NP (D the)
                  (N expense)
                  (PP (P of)
                      (NP (ADJ key)
                          (ADJ subdominant)
                          (NS reactivities)))))
          (. .))
  (ID 49_nonfiction_GENIA-1999;99102590,3;NE))

( (IP-MAT (ADVP-LOC (ADV Here))
          (NP-SBJ (PRO we))
          (VBP describe)
          (NP-OB1 (D an)
                  (ADJ alternative)
                  (N approach)
                  (, ,)
                  (RRC (VAN based)
                       (PP (P on)
                           (NP (ADJP (FW in)
                                     (FW vitro))
                               (N stimulation)
                               (PP (P with)
                                   (NP (ADJ epitope)
                                       (ADJ peptide-loaded)
                                       (ADJ dendritic)
                                       (NS cells)
                                       (PRN (-LRB- -LRB-)
                                            (NS DCs)
                                            (-RRB- -RRB-)))))))
                  (, ,)
                  (CP-REL (WNP-1 (WPRO which))
                          (C 0)
                          (IP-SUB (NP-SBJ *T*-1)
                                  (VBP allows)
                                  (NP-OB1 (PRO one))
                                  (IP-INF (TO to)
                                          (VB probe)
                                          (NP-OB1 (D the)
                                                  (NPR CTL)
                                                  (N repertoire))
                                          (PP (P for)
                                              (NP (Q any)
                                                  (ADJ individual)
                                                  (N reactivity)
                                                  (PP (P of)
                                                      (NP (N choice)))))))))
          (. ;))
  (ID 50_nonfiction_GENIA-1999;99102590,4;NE))

( (IP-MAT (NP-SBJ (D this)
                  (N method))
          (VBD proved)
          (ADJP (QP (ADV significantly)
                    (QR more))
                (ADJ efficient)
                (PP (P than)
                    (NP (N stimulation)
                        (PP (P with)
                            (NP (N peptide)
                                (FP alone))))))
          (. .))
  (ID 51_nonfiction_GENIA-1999;99102590,4;NE))

( (IP-MAT (IP-PPL (VAG Using)
                  (NP-OB1 (D this)
                          (N approach)))
          (NP-SBJ (PRO we))
          (ADVP (ADV first))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NS reactivities)
                                  (PP (P to)
                                      (NP (D the)
                                          (NML (NP (ADJ immunodominant))
                                               (CONJP (CONJ and)
                                                      (NP (ADJ subdominant)
                                                          (N lytic)
                                                          (COPY *)
                                                          (N cycle)
                                                          (COPY *)
                                                          (NS epitopes)
                                                          (COPY *))))
                                          (RRC (VAN identified)
                                               (PP (P by)
                                                   (NP (NPR T)
                                                       (NS cells)))
                                               (NP-LGS *by*)
                                               (PP (P during)
                                                   (NP (ADJ primary)
                                                       (N EBV)
                                                       (N infection)))))))
                          (BEP are)
                          (ADJP (ADV regularly)
                                (ADJ detectable)
                                (PP (P in)
                                    (NP (D the)
                                        (N CTL)
                                        (N memory)
                                        (PP (P of)
                                            (NP (N virus)
                                                (NS carriers))))))))
          (. ;))
  (ID 52_nonfiction_GENIA-1999;99102590,5;NE))

( (IP-MAT (NP-SBJ (D this))
          (VBP implies)
          (CP-THT (C that)
                  (IP-SUB (PP (P in)
                              (NP (ADJ such)
                                  (NS carriers)))
                          (NP-SBJ (ADJ chronic)
                                  (N virus)
                                  (N replication))
                          (VBP remains)
                          (PP (P under)
                              (NP (ADJ direct)
                                  (N T-cell)
                                  (N control)))))
          (. .))
  (ID 53_nonfiction_GENIA-1999;99102590,5;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (ADVP (ADVR further))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (ADJ subdominant)
                                  (ADJ latent)
                                  (ADJ cycle)
                                  (NS reactivities)
                                  (PP (P to)
                                      (NP (NS epitopes)
                                          (PP (P in)
                                              (NP (PRN (D the)
                                                       (ADJ latent)
                                                       (N membrane)
                                                       (N protein))
                                                  (NPR LMP2))))))
                          (, ,)
                          (PP (P though)
                              (ADJP (ADV rarely)
                                    (ADJ undetectable)
                                    (PP (P in)
                                        (NP (ADJP (ADJ LCL-stimulated))
                                            (NS populations)))))
                          (, ,)
                          (MD can)
                          (VP (VP (BE be)
                                  (COPY *)
                                  (VAN reactivated)
                                  (PP (P by)
                                      (NP (N DC)
                                          (N stimulation)))
                                  (NP-LGS *by*))
                              (CONJP (CONJ and)
                                     (VP (ADVP (ADV selectively))
                                         (VBN expanded)
                                         (PP (P as)
                                             (NP (ADJ polyclonal)
                                                 (N CTL)
                                                 (NS lines))))))))
          (. ;))
  (ID 54_nonfiction_GENIA-1999;99102590,6;NE))

( (IP-MAT (NP-SBJ (D the)
                  (ADJ adoptive)
                  (N transfer)
                  (PP (P of)
                      (NP (ADJ such)
                          (NS preparations))))
          (MD may)
          (BE be)
          (PP (P of)
              (NP (N value)))
          (PP (P in)
              (IP-PPL (VAG targeting)
                      (NP-OB1 (ADJ certain)
                              (ADJP (ADJ EBV-positive))
                              (NS malignancies))))
          (. .))
  (ID 55_nonfiction_GENIA-1999;99102590,6;NE))

( (FRAG (NP (NML (NP (ADJ Differential)
                     (N monocyte)
                     (N adhesion))
                 (CONJP (CONJ and)
                        (NP (N adhesion)
                            (N molecule)
                            (N expression))))
            (PP (P in)
                (NP (NP (ADJ venous))
                    (CONJP (CONJ and)
                           (NP (ADJ arterial)
                               (ADJ endothelial)
                               (COPY *)
                               (NS cells)
                               (COPY *))))))
        (. .))
  (ID 56_nonfiction_GENIA-1999;99103960,1;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBD compared)
          (NP-OB1 (NP (NPR U-937)
                      (N cell)
                      (N adhesion))
                  (CONJP (CONJ and)
                         (NP (N adhesion)
                             (N molecule)
                             (N expression))))
          (PP (P in)
              (NP (PRN (NP (NP (ADJ human)
                               (ADJ umbilical)
                               (ADJ venous)
                               (PRN (-LRB- -LRB-)
                                    (NS HUVECs)
                                    (-RRB- -RRB-)))
                           (CONJP (CONJ and)
                                  (NP (ADJ arterial)
                                      (PRN (-LRB- -LRB-)
                                           (NS HUAECs)
                                           (-RRB- -RRB-))
                                      (N endothelial)))))
                  (NS cells)
                  (RRC (VAN exposed)
                       (PP (P to)
                           (NP (NP (N tumor)
                                   (N necrosis)
                                   (N factor)
                                   (PRN (-LRB- -LRB-)
                                        (NPR TNF)
                                        (-RRB- -RRB-)))
                               (, ,)
                               (CONJP (NP (NPR interleukin-1)))
                               (, ,)
                               (CONJP (CONJ and)
                                      (NP (N lipopolysaccharide)
                                          (PRN (-LRB- -LRB-)
                                               (NPR LPS)
                                               (-RRB- -RRB-)))))))))
          (. .))
  (ID 57_nonfiction_GENIA-1999;99103960,2;NE))

( (IP-MAT (NP-SBJ (NP (NPR TNF))
                  (CONJP (CONJ and)
                         (NP (NPR LPS))))
          (VBD stimulated)
          (NP-OB1 (NP (ADJ vascular)
                      (N cell)
                      (N adhesion)
                      (N molecule)
                      (PRN (-LRB- -LRB-)
                           (N VCAM)
                           (-RRB- -RRB-))
                      (N -1)
                      (N surface)
                      (N expression))
                  (CONJP (CONJ and)
                         (NP (N adhesion)
                             (PP (P of)
                                 (NP (NPR U-937)
                                     (ADJ monocyte-like)
                                     (NS cells)))
                             (PP (PP (P to)
                                     (NP (NS HUVECs)))
                                 (CONJP (CONJ but)
                                        (PP (NEG not)
                                            (P to)
                                            (NP (NS HUAECs))))))))
          (. .))
  (ID 58_nonfiction_GENIA-1999;99103960,3;NE))

( (IP-MAT (NP-SBJ (N Antibody)
                  (NS studies))
          (VBD demonstrated)
          (CP-THT (C that)
                  (IP-SUB (PP (P in)
                              (NP (NS HUVECs)))
                          (NP-SBJ (PP (P at)
                                      (NP (QS least)))
                                  (NUM 75)
                                  (N %)
                                  (PP (P of)
                                      (NP (D the)
                                          (N adhesion)
                                          (N response))))
                          (BEP is)
                          (ADJP (NP (NPR VCAM-1))
                                (ADJ mediated))))
          (. .))
  (ID 59_nonfiction_GENIA-1999;99103960,4;NE))

( (IP-MAT (NP-SBJ (NPR Interleukin-1))
          (VBD stimulated)
          (NP-OB1 (NP (NPR U-937)
                      (N cell)
                      (N adhesion)
                      (PP (P to)
                          (NP *ICH*-2)))
                  (CONJP (CONJ and)
                         (NP (NPR VCAM-1)
                             (N surface)
                             (N expression)
                             (PP (P in)
                                 (NP *ICH*-2))))
                  (NP-2 (BIND *group*)
                        (Q both)
                        (NML (NP (NS HUVECs))
                             (CONJP (CONJ and)
                                    (NP (NS HUAECs))))))
          (. .))
  (ID 60_nonfiction_GENIA-1999;99103960,5;NE))

( (IP-MAT (NP-SBJ (NP (NPR Pyrrolidinedithiocarbamate))
                  (CONJP (CONJ and)
                         (NP (PRN (D the)
                                  (N proteasome)
                                  (N inhibitor))
                             (NPR MG-132))))
          (VBD blocked)
          (NP-OB1 (ADJP (NP (NP (NPR TNF-))
                            (CONJP (CONJ and)
                                   (NP (NPR LPS-))))
                        (ADJ stimulated))
                  (NPR U-937)
                  (N cell)
                  (N adhesion)
                  (PP (P to)
                      (NP (NS HUVECs))))
          (. .))
  (ID 61_nonfiction_GENIA-1999;99103960,6;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS agents))
          (ADVP (ADV also))
          (ADVP (ADV significantly))
          (VBD decreased)
          (NP-OB1 (ADJP (NP (NP (NPR TNF-))
                            (CONJP (CONJ and)
                                   (NP (NPR LPS-))))
                        (ADJ stimulated))
                  (NS increases)
                  (PP (P in)
                      (NP (PRN (N HUVEC)
                               (N surface))
                          (NPR VCAM-1))))
          (. .))
  (ID 62_nonfiction_GENIA-1999;99103960,7;NE))

( (IP-MAT (NP-SBJ (NPR TNF))
          (VBD increased)
          (NP-OB1 (NP (NPR VCAM-1)
                      (N protein))
                  (CONJP (CONJ and)
                         (NP (NPR mRNA))))
          (PP (P in)
              (NP (NS HUVECs)
                  (CP-REL (WNP-2 0)
                          (C that)
                          (IP-SUB (NP-SBJ *T*-2)
                                  (BED was)
                                  (VAN blocked)
                                  (PP (P by)
                                      (NP (NPR pyrrolidinedithiocarbamate)))
                                  (NP-LGS *by*)))))
          (. .))
  (ID 63_nonfiction_GENIA-1999;99103960,8;NE))

( (IP-MAT (ADVP (ADV However))
          (, ,)
          (NP-SBJ (CONJ neither)
                  (NP (NPR TNF))
                  (CONJP (CONJ or)
                         (NP (NPR LPS))))
          (VBD stimulated)
          (NP-OB1 (NPR VCAM-1)
                  (N expression)
                  (PP (P in)
                      (NP (NS HUAECs))))
          (. .))
  (ID 64_nonfiction_GENIA-1999;99103960,9;NE))

( (IP-MAT (NP-SBJ (NPR TNF))
          (VBD stimulated)
          (NP-OB1 (N expression)
                  (PP (P of)
                      (NP (BIND *group*)
                          (Q both)
                          (NML (NP (ADJ intercellular)
                                   (N adhesion)
                                   (N molecule-1))
                               (CONJP (CONJ and)
                                      (NP (NPR E-selectin))))))
                  (PP (P in)
                      (NP (NS HUVECs))))
          (, ,))
  (ID 65_nonfiction_GENIA-1999;99103960,10;NE))

( (IP-MAT (CONJ but)
          (PP (P in)
              (NP (NS HUAECs)))
          (, ,)
          (NP-SBJ (FP only)
                  (ADJ intercellular)
                  (N adhesion)
                  (N molecule-1))
          (BED was)
          (VAN increased)
          (. .))
  (ID 66_nonfiction_GENIA-1999;99103960,10;NE))

( (IP-MAT (NP-SBJ (ADJ Electrophoretic)
                  (N mobility)
                  (N shift)
                  (NS assays))
          (VBD demonstrated)
          (NP-OB1 (Q no)
                  (N difference)
                  (PP (P in)
                      (NP (D the)
                          (N pattern)
                          (PP (P of)
                              (NP (ADJP (NP (NPR TNF-))
                                        (ADJ stimulated))
                                  (ADJ nuclear)
                                  (N factor)
                                  (N -kappaB)
                                  (N activation)))))
                  (PP (P between)
                      (NP (NP (NS HUVECs))
                          (CONJP (CONJ and)
                                 (NP (NS HUAECs))))))
          (. .))
  (ID 67_nonfiction_GENIA-1999;99103960,11;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS studies))
          (VP (VP (VBP demonstrate)
                  (NP-OB1 (D a)
                          (ADJP (ADJP (ADJ novel))
                                (CONJP (CONJ and)
                                       (ADJP (ADJ striking))))
                          (N insensitivity)
                          (PP (P of)
                              (NP (ADJ arterial)
                                  (N endothelium)))
                          (PP (P to)
                              (NP (D the)
                                  (NS effects)
                                  (PP (P of)
                                      (NP (NP (NPR TNF))
                                          (CONJP (CONJ and)
                                                 (NP (NPR LPS)))))))))
              (CONJP (CONJ and)
                     (VP (VBP indicate)
                         (NP-OB1 (D a)
                                 (N dissociation)
                                 (PP (P between)
                                     (NP (D the)
                                         (N ability)
                                         (PP (P of)
                                             (NP (NS HUAECs)))
                                         (IP-INF (TO to)
                                                 (VB upregulate)
                                                 (NP-OB1 (NP (ADJ nuclear)
                                                             (N factor)
                                                             (N -kappaB))
                                                         (CONJP (CONJ and)
                                                                (NP (NPR VCAM-1)))))))))))
          (. .))
  (ID 68_nonfiction_GENIA-1999;99103960,12;NE))

( (IP-MAT (NP-SBJ (N Tissue)
                  (N factor)
                  (N expression)
                  (PP (P of)
                      (NP (ADJ human)
                          (NS monocytes))))
          (BEP is)
          (VAN suppressed)
          (PP (P by)
              (NP (NPR lysophosphatidylcholine)))
          (NP-LGS *by*)
          (. .))
  (ID 69_nonfiction_GENIA-1999;99106021,1;NE))

( (IP-MAT (NP-SBJ (D The)
                  (N expression)
                  (PP (P of)
                      (NP (N tissue)
                          (N factor)
                          (PRN (-LRB- -LRB-)
                               (NPR TF)
                               (-RRB- -RRB-))
                          (, ,)
                          (PRN (D the)
                               (ADJ principal)
                               (N initiator)
                               (PP (P of)
                                   (NP (N coagulation)))))))
          (, ,)
          (BEP is)
          (VAN increased)
          (PP (P during)
              (NP (NP (N inflammation))
                  (CONJP (CONJ and)
                         (NP (N atherosclerosis)))))
          (. .))
  (ID 70_nonfiction_GENIA-1999;99106021,2;NE))

( (IP-MAT (NP-SBJ (Q Both)
                  (NS conditions))
          (BEP are)
          (VAN promoted)
          (PP (P by)
              (NP (NPR lysophosphatidylcholine)
                  (PRN (-LRB- -LRB-)
                       (NPR lysoPC)
                       (-RRB- -RRB-))))
          (NP-LGS *by*)
          (. .))
  (ID 71_nonfiction_GENIA-1999;99106021,3;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBD observed)
          (PP (P in)
              (NP (D the)
                  (ADJ present)
                  (N study)))
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NPR lysoPC))
                          (NP-MSR (-LRB- -LRB-)
                                  (NUMP (NUM 1)
                                        (P to)
                                        (NUM 10))
                                  (N micromol/L)
                                  (-RRB- -RRB-))
                          (ADVP (ADV dose-dependently))
                          (VBD reduced)
                          (NP-OB1 (NPR TF)
                                  (N activity)
                                  (PP (P in)
                                      (NP (ADJ human)
                                          (NS monocytes))))
                          (, ,)
                          (PP (P as)
                              (IP-INF (VAN elicited)
                                      (PP (P by)
                                          (NP (NPR lipopolysaccharide)
                                              (PRN (-LRB- -LRB-)
                                                   (NPR LPS)
                                                   (-RRB- -RRB-))))
                                      (NP-LGS *by*)))))
          (. .))
  (ID 72_nonfiction_GENIA-1999;99106021,4;NE))

( (IP-MAT (NP-SBJ (NP (NPR Lysophosphatidylethanolamine)
                      (PRN (-LRB- -LRB-)
                           (N lysoPE)
                           (-RRB- -RRB-)))
                  (CONJP (CONJ and)
                         (NP (ADJ other)
                             (NS lysophospholipids))))
          (DOD did)
          (NEG not)
          (VB affect)
          (NP-OB1 (ADJP (ADJ LPS-induced))
                  (NPR TF)
                  (N activity)
                  (PP (P of)
                      (NP (ADJ human)
                          (NS monocytes))))
          (. .))
  (ID 73_nonfiction_GENIA-1999;99106021,5;NE))

( (IP-MAT (NP-SBJ (NPR TF)
                  (N antigen)
                  (N expression))
          (PP (P as)
              (IP-PPL (VAN elicited)
                      (PP (P by)
                          (NP (NPR LPS)))
                      (NP-LGS *by*)))
          (BED was)
          (ADVP (ADV also))
          (VAN lowered)
          (PP (P by)
              (NP (NPR lysoPC)))
          (NP-LGS *by*)
          (. .))
  (ID 74_nonfiction_GENIA-1999;99106021,6;NE))

( (IP-MAT (NP-SBJ (NPR Phospholipid)
                  (NS analyses))
          (VBD indicated)
          (NP-OB1 (D a)
                  (ADJ selective)
                  (N increase)
                  (PP (P in)
                      (NP (D the)
                          (NPR lysoPC)
                          (N content)
                          (PP (P of)
                              (NP (D the)
                                  (NS monocytes)))))
                  (PP (P after)
                      (NP (N preincubation)
                          (PP (P with)
                              (NP (D the)
                                  (N lysophospholipid))))))
          (. .))
  (ID 75_nonfiction_GENIA-1999;99106021,7;NE))

( (IP-MAT (NP-SBJ (NPR LysoPC))
          (VBD inhibited)
          (NP-OB1 (D the)
                  (NPR TF)
                  (N activity)
                  (PP (P of)
                      (NP (NPR Mono)
                          (NPR Mac-6)
                          (NS cells)))
                  (PP (P to)
                      (NP (D a)
                          (ADJ similar)
                          (N extent)))
                  (PP (P as)
                      (PP (P in)
                          (NP (D the)
                              (NS monocytes)))))
          (. .))
  (ID 76_nonfiction_GENIA-1999;99106021,8;NE))

( (IP-MAT (NP-SBJ (NP (NPR LPS)
                      (N binding)
                      (PP (P to)
                          (NP (N plasma)
                              (N membrane)
                              (NS receptors))))
                  (CONJP (CONJ and)
                         (NP (N internalization)
                             (PP (P of)
                                 (NP (NPR LPS)))
                             (PP (P into)
                                 (NP (NS monocytes))))))
          (BED were)
          (NEG not)
          (VAN affected)
          (PP (P by)
              (NP (NPR lysoPC)))
          (NP-LGS *by*)
          (. .))
  (ID 77_nonfiction_GENIA-1999;99106021,9;NE))

( (IP-MAT (PP (P In)
              (NP (N contrast)))
          (, ,)
          (NP-SBJ (ADJP (ADJ LPS-mediated))
                  (ADJ nuclear)
                  (N binding)
                  (PP (P of)
                      (NP (ADJ nuclear)
                          (N factor)
                          (N -kappaB/Rel)))
                  (PP (P to)
                      (NP (D a)
                          (ADJP (ADJ TF-specific))
                          (N kappaB)
                          (N site))))
          (BED was)
          (VAN inhibited)
          (PP (P by)
              (NP (NPR lysoPC)))
          (NP-LGS *by*)
          (. .))
  (ID 78_nonfiction_GENIA-1999;99106021,10;NE))

( (IP-MAT (NP-SBJ (N Induction)
                  (PP (P of)
                      (NP (NPR TF)
                          (N mRNA)
                          (N expression)))
                  (PP (P by)
                      (NP (NPR LPS))))
          (VBD tended)
          (IP-INF (TO to)
                  (BE be)
                  (ADVP (ADV partially))
                  (VAN reduced)
                  (PP (P by)
                      (NP (D the)
                          (NPR lysophospholipid)))
                  (NP-LGS *by*))
          (. .))
  (ID 79_nonfiction_GENIA-1999;99106021,11;NE))

( (IP-MAT (NP-SBJ (N Preincubation)
                  (PP (P with)
                      (NP (NPR lysoPC))))
          (VBD increased)
          (NP-OB1 (ADJ monocytic)
                  (N cAMP)
                  (NS levels))
          (. .))
  (ID 80_nonfiction_GENIA-1999;99106021,12;NE))

( (IP-MAT (NP-SBJ (N Inhibition)
                  (PP (P of)
                      (NP (ADJ adenylyl)
                          (N cyclase)))
                  (PP (P by)
                      (NP (N pretreatment)
                          (PP (P with)
                              (NP (ADJ 2'-deoxy-3'-adenosine)
                                  (N monophosphate))))))
          (ADVP (ADV partially))
          (VBD reversed)
          (NP-OB1 (D the)
                  (N inhibition)
                  (PP (P of)
                      (NP (NPR TF)
                          (N activity)
                          (RRC (VAN promoted)
                               (PP (P by)
                                   (NP (NPR lysoPC)))
                               (NP-LGS *by*)))))
          (. .))
  (ID 81_nonfiction_GENIA-1999;99106021,13;NE))

( (IP-MAT (PP (P In)
              (NP (N conclusion)))
          (, ,)
          (NP-SBJ (NPR lysoPC))
          (ADVP (ADV markedly))
          (VBP decreases)
          (NP-OB1 (ADJP (ADJ LPS-mediated))
                  (NPR TF)
                  (N expression)
                  (PP (P of)
                      (NP (ADJ human)
                          (NS monocytes))))
          (, ,)
          (IP-PPL (NP-SBJ (D the)
                          (N effect))
                  (ADVP (ADV probably))
                  (BAG being)
                  (VBN mediated)
                  (PP (P by)
                      (NP (CONJ both)
                          (NP (ADJ transcriptional))
                          (CONJP (CONJ and)
                                 (NP (ADJ posttranscriptional)
                                     (NS mechanisms)
                                     (COPY *))))))
          (. .))
  (ID 82_nonfiction_GENIA-1999;99106021,14;NE))

( (IP-MAT (NP-SBJ (N LysoPC))
          (MD may)
          (ADVP (ADV thus))
          (VB attenuate)
          (NP-OB1 (N activation)
                  (PP (P of)
                      (NP (N coagulation))))
          (PP (P during)
              (NP (NP (N inflammation))
                  (CONJP (CONJ and)
                         (NP (N atherosclerosis)))))
          (. .))
  (ID 83_nonfiction_GENIA-1999;99106021,15;NE))

( (FRAG (NP (ADJ Intranuclear)
            (VBN targeted)
            (N delivery)
            (PP (P of)
                (NP (ADJ functional)
                    (N NF-kappaB)))
            (PP (P by)
                (NP (NPR 70)
                    (NPR kDa)
                    (N heat)
                    (N shock)
                    (N protein))))
        (. .))
  (ID 84_nonfiction_GENIA-1999;99107757,1;NE))

( (IP-MAT (NP-SBJ (D The)
                  (NPR 70)
                  (NPR kDa)
                  (N heat)
                  (N shock)
                  (N protein)
                  (PRN (-LRB- -LRB-)
                       (NPR Hsp70)
                       (-RRB- -RRB-)))
          (BEP is)
          (NP-OB1 (D a)
                  (ADJP (ADV highly)
                        (VBN conserved))
                  (, ,)
                  (ADJ ubiquitous)
                  (N protein)
                  (RRC (VBD involved)
                       (PP (P in)
                           (IP-PPL (VAG chaperoning)
                                   (NP-OB1 (NS proteins))
                                   (PP (P to)
                                       (NP (ADJ various)
                                           (ADJ cellular)
                                           (NS organelles)))))))
          (. .))
  (ID 85_nonfiction_GENIA-1999;99107757,2;NE))

( (IP-MAT (ADVP-LOC (ADV Here))
          (NP-SBJ (PRO we))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (PP (P when)
                              (IP-PPL (VBN added)
                                      (ADVP (ADV exogenously))
                                      (PP (P to)
                                          (NP (NS cells)))))
                          (CND *)
                          (, ,)
                          (NP-SBJ (NPR Hsp70))
                          (BEP is)
                          (ADVP (ADV readily))
                          (VBN imported)
                          (PP (P into)
                              (NP (CONJ both)
                                  (NP (ADJ cytoplasmic))
                                  (CONJP (CONJ and)
                                         (NP (ADJ nuclear)
                                             (NS compartments)
                                             (COPY *)))))
                          (PP (P in)
                              (NP (D a)
                                  (ADJ cell-type-specific)
                                  (N fashion)))))
          (. .))
  (ID 86_nonfiction_GENIA-1999;99107757,3;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBD exploited)
          (NP-OB1 (D this)
                  (N ability)
                  (PP (P of)
                      (NP (NPR Hsp70)))
                  (IP-INF (TO to)
                          (VB deliver)
                          (NP-OB1 (NPR NF-kappaB)
                                  (, ,)
                                  (PRN (D a)
                                       (ADJ key)
                                       (ADJ transcriptional)
                                       (N regulator)
                                       (PP (P of)
                                           (NP (ADJ inflammatory)
                                               (NS responses)))))))
          (. .))
  (ID 87_nonfiction_GENIA-1999;99107757,4;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBP demonstrate)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D a)
                                  (N fusion)
                                  (N protein)
                                  (RRC (VAN composed)
                                       (PP (P of)
                                           (NP (NP (D a)
                                                   (ADJ C-terminal)
                                                   (NPR Hsp70)
                                                   (N peptide))
                                               (CONJP (CONJ and)
                                                      (NP (D the)
                                                          (N p50)
                                                          (N subunit)
                                                          (PP (P of)
                                                              (NP (NPR NF-kappaB)))))))))
                          (VP (VP (BED was)
                                  (VAN directed)
                                  (PP (P into)
                                      (NP (D the)
                                          (N nucleus)
                                          (PP (P of)
                                              (NP (NS cells))))))
                              (, ,)
                              (CONJP (VP (MD could)
                                         (VB bind)
                                         (NP-OB1 (N DNA))
                                         (ADVP (ADV specifically))))
                              (, ,)
                              (CONJP (CONJ and)
                                     (VP (VBD activated)
                                         (NP-OB1 (NP (NPR Igkappa)
                                                     (N expression))
                                                 (CONJP (CONJ and)
                                                        (NP (NPR TNFalpha)
                                                            (N production)))))))))
          (. .))
  (ID 88_nonfiction_GENIA-1999;99107757,5;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (ADVP (ADV therefore))
          (VBP propose)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NPR Hsp70))
                          (MD can)
                          (BE be)
                          (VAN used)
                          (PP (P as)
                              (NP (D a)
                                  (N vehicle)
                                  (PP (P for)
                                      (NP (NML (NP (ADJ intracytoplasmic))
                                               (CONJP (CONJ and)
                                                      (NP (ADJ intranuclear)
                                                          (N delivery)
                                                          (COPY *))))
                                          (PP (P of)
                                              (NP (NP (NS proteins))
                                                  (CONJP (CONJ or)
                                                         (NP (N DNA)))))))))
                          (IP-INF (IP-INF (TO to)
                                          (VB modulate)
                                          (NP-OB1 (N gene)
                                                  (N expression)))
                                  (CONJP (CONJ and)
                                         (IP-INF (ADVP (ADV thereby))
                                                 (TO *)
                                                 (VB control)
                                                 (NP-OB1 (ADJ immune)
                                                         (NS responses)))))))
          (. .))
  (ID 89_nonfiction_GENIA-1999;99107757,6;NE))

( (FRAG (NP (N Regulation)
            (PP (P of)
                (NP (NPR IL-4)
                    (N expression)))
            (PP (P by)
                (NP (PRN (D the)
                         (N transcription)
                         (N factor))
                    (NPR JunB)))
            (PP (P during)
                (NP (NPR T)
                    (N helper)
                    (N cell)
                    (N differentiation))))
        (. .))
  (ID 90_nonfiction_GENIA-1999;99107758,1;NE))

( (IP-MAT (NP-SBJ (D The)
                  (ADJ molecular)
                  (N basis)
                  (PP (P for)
                      (NP (ADJ restricted)
                          (N cytokine)
                          (N expression)
                          (PP (P by)
                              (NP (PRN (NP (NP (NPR T)
                                               (NPR helper)
                                               (NPR 1)
                                               (PRN (-LRB- -LRB-)
                                                    (NPR Th1)
                                                    (-RRB- -RRB-)))
                                           (CONJP (CONJ and)
                                                  (NP (NPR T)
                                                      (NPR helper)
                                                      (NPR 2)
                                                      (PRN (-LRB- -LRB-)
                                                           (NPR Th2)
                                                           (-RRB- -RRB-))))))
                                  (NS cells))))))
          (BEP is)
          (ADJP (ADJ unclear))
          (. .))
  (ID 91_nonfiction_GENIA-1999;99107758,2;NE))

( (IP-MAT (NP-SBJ (ADJ Previous)
                  (NS studies))
          (VBD found)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NPR P1)
                                  (, ,)
                                  (PRN (D an)
                                       (N element)
                                       (PP (P of)
                                           (NP (D the)
                                               (NPR interleukin)
                                               (NPR 4)
                                               (PRN (-LRB- -LRB-)
                                                    (NPR IL-4)
                                                    (-RRB- -RRB-))
                                               (N promoter)
                                               (CP-REL (WNP-2 0)
                                                       (C that)
                                                       (IP-SUB (NP-SBJ *T*-2)
                                                               (VBP binds)
                                                               (NP-OB1 (NPR AP-1))))))))
                          (, ,)
                          (BEP is)
                          (ADJP (ADJ important)
                                (PP (P for)
                                    (NP (ADJP (ADJ Th2-restricted))
                                        (NPR IL-4)
                                        (N expression))))))
          (. .))
  (ID 92_nonfiction_GENIA-1999;99107758,3;NE))

( (IP-MAT (ADVP-LOC (ADV Here))
          (NP-SBJ (PRO we))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NP (NPR JunB))
                                  (, ,)
                                  (CONJP (CONJ but)
                                         (NP (NEG not)
                                             (D the)
                                             (ADJ other)
                                             (NPR Jun)
                                             (N family)
                                             (NS members))))
                          (, ,)
                          (BED was)
                          (ADVP (ADV selectively))
                          (VAN induced)
                          (PP (PP (P in)
                                  (NP (NPR Th2)
                                      (NS cells)))
                              (CONJP (CONJ and)
                                     (PP (NEG not)
                                         (P in)
                                         (NP (NPR Th1)
                                             (NS cells)))))
                          (PP (P during)
                              (NP (N differentiation)))))
          (. .))
  (ID 93_nonfiction_GENIA-1999;99107758,4;NE))

( (IP-MAT (NP-SBJ (NPR JunB))
          (HVP has)
          (ADVP-TMP (ADV previously))
          (BEN been)
          (VAN considered)
          (IP-INF (TO to)
                  (BE be)
                  (NP-OB1 (D a)
                          (ADJ negative)
                          (N regulator)
                          (PP (P of)
                              (NP (N transcription)))))
          (. .))
  (ID 94_nonfiction_GENIA-1999;99107758,5;NE))

( (IP-MAT (ADVP (ADV However))
          (, ,)
          (NP-SBJ (PRO we))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NPR JunB))
                          (VP (VP (VBP binds)
                                  (ADVP (ADV directly))
                                  (PP (P to)
                                      (NP (D the)
                                          (N P1)
                                          (N site))))
                              (CONJP (CONJ and)
                                     (VP (VBP synergizes)
                                         (PP (P with)
                                             (NP (NPR c-Maf)))
                                         (IP-INF-PRP (TO to)
                                                     (VB activate)
                                                     (NP-OB1 (D an)
                                                             (NPR IL-4)
                                                             (N luciferase)
                                                             (N reporter)
                                                             (N gene))))))))
          (. .))
  (ID 95_nonfiction_GENIA-1999;99107758,6;NE))

( (IP-MAT (NP-SBJ (NPR JunB)
                  (N -control)
                  (PP (P of)
                      (NP (NPR IL-4)
                          (N expression))))
          (BEP is)
          (VBN mediated)
          (PP (P by)
              (NP (D the)
                  (N phosphorylation)
                  (PP (P of)
                      (NP (NPR JunB)))
                  (PP (P at)
                      (NP (NP (NPR Thr102))
                          (CONJP (CONJ and)
                                 (NP (NPR -104)))))
                  (PP (P by)
                      (NP (N JNK)
                          (N MAP)
                          (N kinase)))))
          (. .))
  (ID 96_nonfiction_GENIA-1999;99107758,7;NE))

( (IP-MAT (NP-SBJ (D The)
                  (N synergy)
                  (PP (P between)
                      (NP (NP (NPR c-Maf))
                          (CONJP (CONJ and)
                                 (NP (NPR JunB))))))
          (MD can)
          (BE be)
          (VAN attributed)
          (PP (P to)
              (NP (ADJ cooperative)
                  (N DNA)
                  (N binding)
                  (, ,)
                  (CP-REL (WNP-1 (WPRO which))
                          (C 0)
                          (IP-SUB (NP-SBJ *T*-1)
                                  (BEP is)
                                  (VBN facilitated)
                                  (PP (P by)
                                      (NP (NPR JunB)
                                          (N phosphorylation)))))))
          (. .))
  (ID 97_nonfiction_GENIA-1999;99107758,8;NE))

( (IP-MAT (PP (P In)
              (NP (ADJ transgenic)
                  (NS mice)))
          (, ,)
          (NP-SBJ (ADJ elevated)
                  (NPR JunB)
                  (NS levels))
          (VBD caused)
          (NP-OB1 (VBN increased)
                  (N expression)
                  (PP (P of)
                      (NP (Q several)
                          (NPR Th2)
                          (NS cytokines)))
                  (PP (P in)
                      (NP (VAG developing)
                          (NPR Th1)
                          (NS cells))))
          (. .))
  (ID 98_nonfiction_GENIA-1999;99107758,9;NE))

( (IP-MAT (NP-SBJ (NPR JunB))
          (ADVP (ADV also))
          (VBD upregulated)
          (NP-OB1 (NPR IL-4)
                  (N expression)
                  (PP (P in)
                      (NP (N response)
                          (PP (P to)
                              (NP (N immunization))))))
          (. .))
  (ID 99_nonfiction_GENIA-1999;99107758,10;NE))

( (IP-MAT (ADVP (ADV Thus))
          (, ,)
          (NP-SBJ (D the)
                  (ADJ early)
                  (N increase)
                  (PP (P of)
                      (NP (NPR JunB)
                          (N protein)))
                  (PP (P in)
                      (NP (NPR Th2)
                          (NS cells))))
          (VP (VP (MD can)
                  (VB provide)
                  (NP-OB1 (D the)
                          (N specificity)
                          (PP (P for)
                              (NP (NPR c-Maf)))
                          (PP (P in)
                              (NP (NPR IL-4)
                                  (N expression))))
                  (PP (P during)
                      (NP (NPR T)
                          (N cell)
                          (N development))))
              (CONJP (CONJ and)
                     (VP (VBP directs)
                         (ADVP (ADV thereby))
                         (NP-OB1 (NPR Th2)
                                 (N differentiation)))))
          (. .))
  (ID 100_nonfiction_GENIA-1999;99107758,11;NE))

( (FRAG (NP (NP (ADJ Immunohistochemical)
                (N study)
                (PP (P of)
                    (NP (ADJP (ADJ c-fos-positive))
                        (NS lymphocytes)
                        (RRC (VBN infiltrated)
                             (PP (P into)
                                 (NP (ADJ human)
                                     (ADJ squamous)
                                     (N cell)
                                     (NS carcinomas)
                                     (PP (P of)
                                         (NP (D the)
                                             (NML (NP (N head))
                                                  (CONJP (CONJ and)
                                                         (NP (N neck))))))))
                             (PP (P during)
                                 (NP (N radiation)
                                     (N therapy)))))))
            (CONJP (CONJ and)
                   (NP (NP-POS (PRO its))
                       (ADJ clinical)
                       (N significance))))
        (. .))
  (ID 101_nonfiction_GENIA-1999;99111186,1;NE))

( (IP-MAT (NP-SBJ (NPR C-fos))
          (HVP has)
          (BEN been)
          (VAN reported)
          (IP-INF (TO to)
                  (BE be)
                  (NP-OB1 (NUM one)
                          (PP (P of)
                              (NP (D the)
                                  (ADJ immediate)
                                  (ADJ early)
                                  (NS genes)
                                  (PP (P in)
                                      (NP (N signal)
                                          (N transduction)
                                          (NS systems))))))
                  (PP (P after)
                      (NP (Q many)
                          (NS kinds)
                          (PP (P of)
                              (NP (NS stresses)))
                          (, ,)
                          (RRC (VAG including)
                               (NP-OB1 (VAG ionizing)
                                       (N radiation))))))
          (. .))
  (ID 102_nonfiction_GENIA-1999;99111186,2;NE))

( (IP-MAT (NP-SBJ (NS Changes)
                  (PP (P in)
                      (NP (NPR c-fos)
                          (N expression)
                          (RRC (VBN induced)
                               (PP (P by)
                                   (NP (N radiation)
                                       (N therapy)))
                               (PP (P in)
                                   (NP (N tumor)
                                       (NS tissues)))))))
          (HVP have)
          (NEG not)
          (ADVP-TMP (ADV yet))
          (BEN been)
          (VAN reported)
          (. .))
  (ID 103_nonfiction_GENIA-1999;99111186,3;NE))

( (IP-MAT (PP (P In)
              (NP (D this)
                  (N study)))
          (, ,)
          (NP-SBJ (PRO we))
          (HVP have)
          (VBN attempted)
          (IP-INF (IP-INF (TO to)
                          (VB determine)
                          (CP-QUE (WQ whether)
                                  (C 0)
                                  (IP-SUB (NP-SBJ (NPR c-fos)
                                                  (N expression))
                                          (BEP is)
                                          (VBN induced)
                                          (PP (P by)
                                              (NP (N radiotherapy)))
                                          (PP (P in)
                                              (NP (ADJ human)
                                                  (ADJ squamous)
                                                  (N cell)
                                                  (NS carcinomas)
                                                  (PP (P of)
                                                      (NP (D the)
                                                          (NML (NP (N head))
                                                               (CONJP (CONJ and)
                                                                      (NP (N neck)))))))))))
                  (CONJP (CONJ and)
                         (IP-INF (TO to)
                                 (VB establish)
                                 (NP-OB1 (D a)
                                         (ADJ possible)
                                         (N correlation)
                                         (PP (P between)
                                             (NP (NP (NPR c-fos)
                                                     (N expression))
                                                 (CONJP (CONJ and)
                                                        (NP (D the)
                                                            (ADJ therapeutic)
                                                            (NS effects)
                                                            (PP (P of)
                                                                (NP (N radiation)
                                                                    (N therapy)))))))))))
          (. .))
  (ID 104_nonfiction_GENIA-1999;99111186,4;NE))

( (IP-MAT (NP-SBJ (NUM Twenty-seven)
                  (NS patients)
                  (PP (P with)
                      (NP (NS tumors)
                          (PP (P of)
                              (NP (D the)
                                  (NML (NP (ADJ oral)
                                           (N cavity))
                                       (, ,)
                                       (CONJP (NP (N oropharynx)))
                                       (, ,)
                                       (CONJP (CONJ and)
                                              (NP (ADJ maxillary)
                                                  (N sinus))))))
                          (CP-REL *ICH*-1))))
          (BED were)
          (VAN examined)
          (, ,)
          (CP-REL-1 (WNP-2 (Q all)
                           (WPP (P of)
                                (WNP (WPRO which))))
                    (C 0)
                    (IP-SUB (NP-SBJ *T*-2)
                            (BED were)
                            (VAN confirmed)
                            (PP (P as)
                                (NP (ADJ squamous)
                                    (N cell)
                                    (NS carcinomas)))))
          (. .))
  (ID 105_nonfiction_GENIA-1999;99111186,5;NE))

( (IP-MAT (PP (P After)
              (IP-PPL (VAG obtaining)
                      (NP-OB1 (NP-POS (D the)
                                      (NS patients)
                                      (POS '))
                              (VBN informed)
                              (N consent))))
          (CRD *)
          (, ,)
          (NP-SBJ (NS biopsies))
          (BED were)
          (VAN performed)
          (PP (PP (P before)
                  (NP (N treatment)))
              (CONJP (CONJ and)
                     (PP (P at)
                         (NP (NS doses)
                             (PP (P of)
                                 (NP (NUMP (NUM 4)
                                           (, ,)
                                           (NUM 10)
                                           (, ,)
                                           (CONJ and)
                                           (NUM 20))
                                     (N Gy)
                                     (PP (P of)
                                         (NP (N radiotherapy)))))))))
          (. .))
  (ID 106_nonfiction_GENIA-1999;99111186,6;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (D the)
                  (NS specimens))
          (BED were)
          (VAN preserved)
          (PP (P in)
              (NP (ADJ liquid)
                  (N nitrogen)))
          (PP (P for)
              (NP (ADJR further)
                  (N examination)))
          (, ,))
  (ID 107_nonfiction_GENIA-1999;99111186,6;NE))

( (IP-MAT (NP-SBJ (ADJ Serial)
                  (N sectioning)
                  (PP (P of)
                      (NP (NUM 6)
                          (N micrometer))))
          (BED was)
          (VAN performed)
          (IP-PPL (VAG using)
                  (NP-OB1 (D a)
                          (N cryostat)))
          (, ,))
  (ID 108_nonfiction_GENIA-1999;99111186,7;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (NS samples))
          (BED were)
          (ADVP (ADV immunohistochemically))
          (VAN stained)
          (IP-PPL (VAG using)
                  (NP-OB1 (NP (D the)
                              (ADJ streptoavidin-biotin)
                              (N peroxidase)
                              (N method))
                          (CONJP (CONJ and)
                                 (NP (D a)
                                     (ADJ monoclonal)
                                     (N antibody)
                                     (PP (P against)
                                         (NP (NPR c-fos)))))))
          (. .))
  (ID 109_nonfiction_GENIA-1999;99111186,7;NE))

( (IP-MAT (NP-SBJ (NUM Three)
                  (PP (P of)
                      (NP (D the)
                          (NUM 27)
                          (NS patients)))
                  (PP (P with)
                      (NP (NPR squamous)
                          (NPR cell)
                          (NPR carcinoma))))
          (VBD showed)
          (NP-OB1 (ADJ slight)
                  (N expression)
                  (PP (P of)
                      (NP (NPR c-fos))))
          (PP (P in)
              (NP (NP-POS (PRO their))
                  (N tumor)
                  (NS cells)))
          (PP (PP (P before))
              (CONJP (CONJ and/or)
                     (PP (P at)))
              (NP (NUMP (NUM 4)
                        (CONJ or)
                        (NUM 10))
                  (N Gy)
                  (PP (P of)
                      (NP (N radiotherapy)))))
          (. .))
  (ID 110_nonfiction_GENIA-1999;99111186,8;NE))

( (IP-MAT (NP-SBJ (D The)
                  (NS tumors))
          (VBD showed)
          (NP-OB1 (ADJ high)
                  (N radiosensitivity))
          (. .))
  (ID 111_nonfiction_GENIA-1999;99111186,9;NE))

( (IP-MAT (IP-PPL (VAG Concerning)
                  (NP-OB1 (ADJ tumor-infiltrating)
                          (NS lymphocytes)))
          (, ,)
          (NP-SBJ (D the)
                  (N rate)
                  (PP (P of)
                      (NP (NML (NP (ADJ moderate))
                               (CONJP (CONJ or)
                                      (NP (ADJ remarkable)
                                          (NS grades)
                                          (COPY *))))
                          (PP (P of)
                              (NP (ADJP (ADJ c-fos-positive))
                                  (NS lymphocytes)))))
                  (PP (PP (P before)
                          (NP (N radiotherapy)))
                      (CONJP (CONJ and)
                             (PP (P at)
                                 (NP (N radiation)
                                     (NS doses)
                                     (PP (P of)
                                         (NP (NP (NUM 4))
                                             (, ,)
                                             (CONJP (NP (NUM 10)))
                                             (, ,)
                                             (CONJP (CONJ and)
                                                    (NP (NUM 20)
                                                        (N Gy)
                                                        (COPY *))))))))))
          (BED was)
          (NP-OB1 (NP (NUM 8.0))
                  (, ,)
                  (CONJP (NP (NUM 29.2)))
                  (, ,)
                  (CONJP (NP (NUM 4.8)))
                  (, ,)
                  (CONJP (CONJ and)
                         (NP (NUM 0)
                             (N %)
                             (COPY *))))
          (, ,)
          (ADVP (ADV respectively))
          (. .))
  (ID 112_nonfiction_GENIA-1999;99111186,10;NE))

( (IP-MAT (NP-SBJ (D The)
                  (N relationship)
                  (PP (P between)
                      (NP (NP (D the)
                              (ADJ immunohistochemical)
                              (NS findings))
                          (CONJP (CONJ and)
                                 (NP (D the)
                                     (N antitumor)
                                     (N effect)
                                     (PP (P at)
                                         (NP (D a)
                                             (N radiation)
                                             (N dose)
                                             (PP (P of)
                                                 (NP (NUM 20)
                                                     (N Gy))))))))))
          (BED was)
          (VAN examined)
          (PP (P on)
              (NP (D the)
                  (ADJ corresponding)
                  (ADJP (NP (NP (NPR H))
                            (CONJP (CONJ &)
                                   (NP (NPR E))))
                        (ADJ -stained))
                  (NS sections)))
          (. .))
  (ID 113_nonfiction_GENIA-1999;99111186,11;NE))

( (IP-MAT (PP (P In)
              (NP (NS patients)
                  (CP-REL (WNP-1 (NP-POS (WPRO whose))
                                 (N infiltration)
                                 (PP (P of)
                                     (NP (ADJP (ADJ c-fos-positive))
                                         (NS lymphocytes)))
                                 (PP (P into)
                                     (NP (N tumor)
                                         (NS tissues))))
                          (C 0)
                          (IP-SUB (NP-SBJ *T*-1)
                                  (BED were)
                                  (ADJP (ADJP (ADJ moderate))
                                        (CONJP (CONJ or)
                                               (ADJP (ADJ remarkable))))
                                  (PP (P at)
                                      (NP (NUM 4)
                                          (N Gy)
                                          (PP (P of)
                                              (NP (N radiotherapy)))))))))
          (, ,)
          (NP-SBJ (D the)
                  (NS tumors))
          (VBD responded)
          (ADVP (ADV significantly)
                (ADV well))
          (PP (P to)
              (NP (N radiation)
                  (N therapy)))
          (-LRB- -LRB-)
          (CODE (FW P)
                (FW <)
                (FW 0.025)
                (, ,)
                (NP (N chi2)
                    (N test)))
          (-RRB- -RRB-)
          (, ,))
  (ID 114_nonfiction_GENIA-1999;99111186,12;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (D the)
                  (NS patients))
          (VBD took)
          (NP-OB1 (D a)
                  (ADJP (ADV significantly)
                        (ADJ favorable))
                  (ADJ clinical)
                  (N course))
          (-LRB- -LRB-)
          (CODE (FW P)
                (FW <)
                (FW 0.05)
                (, ,)
                (NP (N chi2)
                    (N test)))
          (-RRB- -RRB-)
          (. .))
  (ID 115_nonfiction_GENIA-1999;99111186,12;NE))

( (IP-MAT (PP (P In)
              (NP (D a)
                  (N sample)
                  (PP (P from)
                      (NP (NUM one)
                          (PP (P of)
                              (NP (D the)
                                  (NS patients)))))))
          (, ,)
          (NP-SBJ (ADJP (ADJ c-fos-positive))
                  (NS lymphocytes))
          (BED were)
          (VAN identified)
          (PP (P as)
              (NP (NP (NPR CD4)
                      (NPR positive))
                  (CONJP (CONJ and)
                         (NP (NPR CD8)
                             (NPR negative)))))
          (. .))
  (ID 116_nonfiction_GENIA-1999;99111186,13;NE))

( (IP-MAT (ADVP (ADV Therefore))
          (, ,)
          (NP-SBJ (D the)
                  (ADJ high)
                  (N radiosensitivity)
                  (PP (P of)
                      (NP (ADJ squamous)
                          (N cell)
                          (NS carcinomas)
                          (PP (P in)
                              (NP (NP-POS (PRO our))
                                  (NS samples))))))
          (MD could)
          (BE be)
          (VAN explained)
          (PP (P by)
              (NP (D an)
                  (N overexpression)
                  (PP (P of)
                      (NP (NPR c-fos)))
                  (PP (P in)
                      (NP (D the)
                          (ADJ tumor-infiltrating)
                          (NS lymphocytes)))
                  (RRC (VBN induced)
                       (PP (P by)
                           (NP (ADJ small)
                               (NS doses)
                               (PP (P of)
                                   (NP (N radiation)
                                       (N therapy))))))))
          (NP-LGS *by*)
          (, ,))
  (ID 117_nonfiction_GENIA-1999;99111186,14;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (D these)
                  (VBN activated)
                  (NS lymphocytes))
          (VBD exerted)
          (NP-OB1 (D a)
                  (ADJ cytotoxic)
                  (N effect))
          (PP (P against)
              (NP (D the)
                  (N cancer)
                  (NS cells)))
          (. .))
  (ID 118_nonfiction_GENIA-1999;99111186,14;NE))

( (IP-MAT (NP-SBJ (NPR CD2)
                  (N signalling))
          (VBP induces)
          (NP-OB1 (N phosphorylation)
                  (PP (P of)
                      (NP (NPR CREB))))
          (PP (P in)
              (NP (ADJ primary)
                  (NS lymphocytes)))
          (. .))
  (ID 119_nonfiction_GENIA-1999;99111421,1;NE))

( (IP-MAT (NP-SBJ (N Promoter)
                  (NS sequences)
                  (ADJP (ADJ responsive)
                        (PP (P to)
                            (NP (ADJ cyclic)
                                (N AMP)
                                (PRN (-LRB- -LRB-)
                                     (N cAMP)
                                     (-RRB- -RRB-))))))
          (VP (VP (BEP are)
                  (VBN found)
                  (PP (P in)
                      (NP (D a)
                          (N number)
                          (PP (P of)
                              (NP (ADJ cellular)
                                  (NS genes))))))
              (, ,)
              (CONJP (CONJ and)
                     (VP (VBP bind)
                         (NP-OB1 (N transcription)
                                 (NS factors)
                                 (PP (P of)
                                     (NP (D the)
                                         (N cAMP)
                                         (N response)
                                         (N element)
                                         (N binding)
                                         (N protein)
                                         (PRN (-LRB- -LRB-)
                                              (NPR CREB)
                                              (-RRB- -RRB-))
                                         (, /)
                                         (PRN (ADJ activating)
                                              (N transcription)
                                              (N factor-1)
                                              (PRN (-LRB- -LRB-)
                                                   (N ATF-1)
                                                   (-RRB- -RRB-))
                                              (PRN (N family)))))))))
          (. .))
  (ID 120_nonfiction_GENIA-1999;99111421,2;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (HVP have)
          (VBN used)
          (NP-OB1 (D a)
                  (ADJ human)
                  (ADJ T-lymphotropic)
                  (N virus)
                  (N type)
                  (N 1)
                  (PRN (-LRB- -LRB-)
                       (N HTLV-1)
                       (-RRB- -RRB-))
                  (N model)
                  (PP (P of)
                      (NP (N cAMP)
                          (N response)
                          (N element)
                          (PRN (-LRB- -LRB-)
                               (N CRE)
                               (-RRB- -RRB-))
                          (N transcription))))
          (IP-INF (TO to)
                  (VB investigate)
                  (NP-OB1 (D the)
                          (N influence)
                          (PP (P of)
                              (NP (N lymphocyte)
                                  (N activation)))
                          (PP (P on)
                              (NP (N transcription)
                                  (PP (P from)
                                      (NP (ADJ homologous)
                                          (NS regions)
                                          (PP (P in)
                                              (NP (D the)
                                                  (ADJ viral)
                                                  (N promoter)))))))))
          (. .))
  (ID 121_nonfiction_GENIA-1999;99111421,3;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (ADVP-TMP (ADV previously))
          (VBD demonstrated)
          (NP-OB1 (VAN increased)
                  (NPR HTLV-1)
                  (N transcription)
                  (RRC (VAG following)
                       (NP-OB1 (PRN (NP (NP (NPR CD2))
                                        (CONJP (CONJ but)
                                               (NP (NEG not)
                                                   (NPR CD3)))))
                               (N receptor)
                               (N cross-linking))))
          (. .))
  (ID 122_nonfiction_GENIA-1999;99111421,4;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBD hypothesized)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D this)
                                  (VBN increased)
                                  (ADJ viral)
                                  (N transcription))
                          (BED was)
                          (VBN mediated)
                          (, ,)
                          (PP (P in)
                              (NP (N part)))
                          (, ,)
                          (PP (P through)
                              (NP (D the)
                                  (N phosphorylation)
                                  (PP (P of)
                                      (NP (NPR CREB)))))))
          (. .))
  (ID 123_nonfiction_GENIA-1999;99111421,5;NE))

( (IP-MAT (ADVP (ADV Therefore))
          (, ,)
          (NP-SBJ (PRO we))
          (VBD investigated)
          (NP-OB1 (PRN (NP (NP (NPR CD2))
                           (CONJP (CONJ and)
                                  (NP (NPR CD3)))))
                  (ADJ receptor-mediated)
                  (N signalling))
          (PP (P in)
              (NP (ADJ primary)
                  (ADJ human)
                  (NML (ADJ peripheral)
                       (N blood))
                  (NML (ADJ mononuclear)
                       (NS cells))
                  (PRN (-LRB- -LRB-)
                       (NPR PBMC)
                       (-RRB- -RRB-))))
          (. .))
  (ID 124_nonfiction_GENIA-1999;99111421,6;NE))

( (IP-MAT (NP-SBJ (PRN (NP (NP (NPR CD2))
                           (, ,)
                           (CONJP (CONJ but)
                                  (NP (NEG not)
                                      (NPR CD3)))))
                  (, ,)
                  (N cross-linking))
          (VBD increased)
          (NP-OB1 (NPR cAMP)
                  (RRC (VAN detected)
                       (PP (P by)
                           (NP (ADJ competitive)
                               (ADJP (ADJ enzyme-linked))
                               (N immunosorbent)
                               (N assay)
                               (PRN (-LRB- -LRB-)
                                    (NPR ELISA)
                                    (-RRB- -RRB-))))
                       (NP-LGS *by*)))
          (ADVP (ADV approximately)
                (QP (Q fourfold)))
          (. .))
  (ID 125_nonfiction_GENIA-1999;99111421,7;NE))

( (IP-MAT (NP-SBJ (NPR CD2)
                  (N cross-linking))
          (ADVP (ADV concurrently))
          (VBD increased)
          (NP-OB1 (N phosphorylation)
                  (PP (P of)
                      (NP (NPR CREB)))
                  (RRC (VAN detected)
                       (PP (P by)
                           (NP (N immunoblot)
                               (N assay)))
                       (NP-LGS *by*)))
          (QP (Q eightfold))
          (. .))
  (ID 126_nonfiction_GENIA-1999;99111421,8;NE))

( (IP-MAT (ADJP-SPR (ADJ Consistent)
                    (PP (P with)
                        (NP (ADJ post-translational)
                            (N regulation))))
          (, ,)
          (NP-SBJ (Q no)
                  (N change)
                  (PP (P in)
                      (NP (ADJ total)
                          (N level)
                          (PP (P of)
                              (NP (NPR CREB)
                                  (N protein))))))
          (BED was)
          (VAN observed)
          (. .))
  (ID 127_nonfiction_GENIA-1999;99111421,9;NE))

( (IP-MAT (NP-SBJ (N Phosphorylation)
                  (PP (P of)
                      (NP (NPR CREB))))
          (VBD occurred)
          (PP (P through)
              (NP (D a)
                  (ADJP (NP (NP (NPR herbimycin)
                                (NPR A))
                            (CONJP (CONJ and)
                                   (NP (NPR Rp-cAMP))))
                        (ADJ -sensitive))
                  (N pathway)))
          (, ,)
          (IP-PPL (VAG suggesting)
                  (CP-THT (C 0)
                          (IP-SUB (NP-SBJ (N phosphorylation))
                                  (VBD required)
                                  (NP-OB1 (ADJ antecedent)
                                          (N activation)
                                          (PP (P of)
                                              (NP (BIND *group*)
                                                  (Q both)
                                                  (NML (NP (N protein)
                                                           (N tyrosine)
                                                           (NS kinases)
                                                           (PRN (-LRB- -LRB-)
                                                                (NS PTK)
                                                                (-RRB- -RRB-)))
                                                       (CONJP (CONJ and)
                                                              (NP (N protein)
                                                                  (N kinase)
                                                                  (NPR A)
                                                                  (PRN (-LRB- -LRB-)
                                                                       (NPR PKA)
                                                                       (-RRB- -RRB-)))))))))))
          (. .))
  (ID 128_nonfiction_GENIA-1999;99111421,10;NE))

( (IP-MAT (NP-SBJ (PRN (NP (CONJ Both)
                           (NP (NPR CD2))
                           (CONJP (CONJ and)
                                  (NP (NPR CD3)))))
                  (N cross-linking))
          (VBD increased)
          (NP-OB1 (N binding)
                  (PP (P of)
                      (NP (ADJ nuclear)
                          (NS proteins)))
                  (PP (P to)
                      (NP (D a)
                          (ADJ radiolabelled)
                          (N CRE)
                          (N oligonucleotide)
                          (N probe)))
                  (PP (P in)
                      (NP (ADJ electrophoretic)
                          (N mobility)
                          (N shift)
                          (NS assays))))
          (IP-PPL (VAG suggesting)
                  (CP-THT (C that)
                          (IP-SUB (NP-SBJ (N lymphocyte)
                                          (N activation))
                                  (VBP enhances)
                                  (NP-OB1 (N binding))
                                  (ADVP (ADV independently)
                                        (PP (P of)
                                            (NP (N phosphorylation)
                                                (PP (P of)
                                                    (NP (NPR CREB)))
                                                (PP (P at)
                                                    (NP (NPR serine)
                                                        (NPR 133)))))))))
          (. .))
  (ID 129_nonfiction_GENIA-1999;99111421,11;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS data))
          (VP (VP (VBP indicate)
                  (NP-OB1 (ADJ specific)
                          (N modulation)
                          (PP (P of)
                              (NP (D the)
                                  (NPR CREB/ATF-1)
                                  (N family)
                                  (PP (P of)
                                      (NP (N transcription)
                                          (NS factors)))))
                          (PP (P by)
                              (NP (D the)
                                  (NPR CD2)
                                  (N signalling)
                                  (N pathway)))))
              (CONJP (CONJ and)
                     (VP (VBP suggest)
                         (NP-OB1 (NPR CD2)
                                 (N receptor)
                                 (N modulation)
                                 (PP (P of)
                                     (NP (ADJP (ADJ CRE-mediated))
                                         (N transcription)))
                                 (RRC (VAG following)
                                      (NP-OB1 (N ligand)
                                              (N engagement)))
                                 (PP (-LRB- -LRB-)
                                     (FW e.g.)
                                     (NP (ADJ cell-to-cell)
                                         (N contact))
                                     (-RRB- -RRB-))))))
          (. .))
  (ID 130_nonfiction_GENIA-1999;99111421,12;NE))

( (FRAG (NP (ADJ Protective)
            (NS effects)
            (PP (P of)
                (NP (NPR notch-1)))
            (PP (P on)
                (NP (ADJP (ADJ TCR-induced))
                    (N apoptosis))))
        (. .))
  (ID 131_nonfiction_GENIA-1999;99113717,1;NE))

( (IP-MAT (NP-SBJ (D The)
                  (NPR Notch)
                  (N receptor)
                  (N protein))
          (VP (VP (BED was)
                  (ADVP (ADV originally))
                  (VAN identified)
                  (PP (P in)
                      (NP (NPR Drosophila))))
              (CONJP (CONJ and)
                     (VP (BEP is)
                         (VBN known)
                         (IP-INF (IP-INF (TO to)
                                         (VB mediate)
                                         (NP-OB1 (ADJP (N cell)
                                                       (P to)
                                                       (N cell))
                                                 (N communication)))
                                 (CONJP (CONJ and)
                                        (IP-INF (TO *)
                                                (VB influence)
                                                (NP-OB1 (N cell)
                                                        (N fate)
                                                        (NS decisions))))))))
          (. .))
  (ID 132_nonfiction_GENIA-1999;99113717,2;NE))

( (IP-MAT (NP-SBJ (NS Members)
                  (PP (P of)
                      (NP (D this)
                          (N family))))
          (HVP have)
          (BEN been)
          (VAN isolated)
          (PP (P from)
              (NP (NS invertebrates)))
          (ADVP (ADVR as)
                (ADV well)
                (PP (P as)
                    (NP (NS vertebrates))))
          (. .))
  (ID 133_nonfiction_GENIA-1999;99113717,3;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBD isolated)
          (NP-OB1 (N mouse)
                  (NPR Notch-1))
          (PP (P in)
              (NP (D a)
                  (N yeast)
                  (ADJ two-hybrid)
                  (N screen)))
          (PP (P with)
              (NP (NPR Nur77)
                  (, ,)
                  (CP-REL (WNP-2 (WPRO which))
                          (C 0)
                          (IP-SUB (NP-SBJ *T*-2)
                                  (BEP is)
                                  (NP-OB1 (D a)
                                          (N protein)
                                          (CP-REL (WNP-3 0)
                                                  (C that)
                                                  (IP-SUB (NP-SBJ *T*-3)
                                                          (HVP has)
                                                          (BEN been)
                                                          (VAN shown)
                                                          (ADVP-TMP (ADV previously))
                                                          (IP-INF (TO to)
                                                                  (BE be)
                                                                  (VAN required)
                                                                  (PP (P for)
                                                                      (NP (N apoptosis)
                                                                          (PP (P in)
                                                                              (NP (NPR T)
                                                                                  (N cell)
                                                                                  (NS lines)))))))))))))
          (. .))
  (ID 134_nonfiction_GENIA-1999;99113717,4;NE))

( (IP-MAT (NP-SBJ (D The)
                  (NS data)
                  (RRC (VAN presented)
                       (PP (P below))))
          (VBP indicate)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (NPR Notch-1)
                                  (N expression))
                          (VBP provides)
                          (NP-OB1 (ADJ significant)
                                  (N protection))
                          (PP (P to)
                              (NP (NPR T)
                                  (N cell)
                                  (NS lines)))
                          (PP (P from)
                              (NP (ADJP (ADJ TCR-mediated))
                                  (N apoptosis)))))
          (. .))
  (ID 135_nonfiction_GENIA-1999;99113717,5;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS data))
          (VBP demonstrate)
          (NP-OB1 (D a)
                  (ADJ new)
                  (ADJ antiapoptotic)
                  (N role)
                  (PP (P for)
                      (NP (NPR Notch-1))))
          (, ,)
          (IP-PPL (VAG providing)
                  (NP-OB1 (N evidence)
                          (CP-THT (C that)
                                  (IP-SUB (, ,)
                                          (PP (P in)
                                              (NP (N addition)
                                                  (PP (P to)
                                                      (IP-PPL (VAG regulating)
                                                              (NP-OB1 (N cell)
                                                                      (N fate)
                                                                      (NS decisions))))))
                                          (, ,)
                                          (NP-SBJ (NPR Notch-1))
                                          (MD can)
                                          (VB play)
                                          (NP-OB1 (D a)
                                                  (ADJ critical)
                                                  (N role)
                                                  (PP (P in)
                                                      (IP-PPL (VAG controlling)
                                                              (NP-OB1 (NS levels)
                                                                      (PP (P of)
                                                                          (NP (N cell)
                                                                              (N death)))
                                                                      (PP (P in)
                                                                          (NP (NPR T)
                                                                              (NS cells)))))))))))
          (. .))
  (ID 136_nonfiction_GENIA-1999;99113717,6;NE))

( (IP-MAT (NP-SBJ (NPR T)
                  (N cell)
                  (N priming))
          (VBP enhances)
          (NP-OB1 (NPR IL-4)
                  (N gene)
                  (N expression))
          (PP (P by)
              (IP-PPL (VAG increasing)
                      (NP-OB1 (ADJ nuclear)
                              (N factor)
                              (PP (P of)
                                  (NP (VBN activated)
                                      (NPR T)
                                      (NS cells))))))
          (CRD *)
          (. .))
  (ID 137_nonfiction_GENIA-1999;99113747,1;NE))

( (IP-MAT (NP-SBJ (D The)
                  (ADJ repetitive)
                  (N activation)
                  (PP (P of)
                      (NP (NPR T)
                          (NS cells)))
                  (PRN (-LRB- -LRB-)
                       (N priming)
                       (-RRB- -RRB-)))
          (VBP enhances)
          (NP-OB1 (D the)
                  (N expression)
                  (PP (P of)
                      (NP (NP (Q many)
                              (NS cytokines)
                              (, ,)
                              (ADJP (ADJ such)
                                    (PP (P as)
                                        (NP (NPR IL-4)))))
                          (, ,)
                          (CONJP (P but)
                                 (NP (NEG not)
                                     (NS others)
                                     (, ,)
                                     (ADJP (ADJ such)
                                           (PP (P as)
                                               (NP (NPR IL-2)))))))))
          (. .))
  (ID 138_nonfiction_GENIA-1999;99113747,2;NE))

( (IP-MAT (NP-SBJ (ADJ Molecular)
                  (NS mechanisms)
                  (RRC (VAG underlying)
                       (NP-OB1 (ADJ selective)
                               (N expression)
                               (PP (P of)
                                   (NP (NS cytokines)))
                               (PP (P by)
                                   (NP (NPR T)
                                       (NS cells))))))
          (VBP remain)
          (ADJP (ADV poorly)
                (VBN understood))
          (. .))
  (ID 139_nonfiction_GENIA-1999;99113747,3;NE))

( (IP-MAT (ADVP-LOC (ADV Here))
          (NP-SBJ (PRO we))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (N priming)
                                  (PP (P of)
                                      (NP (NPR CD4)
                                          (NPR T)
                                          (NS cells))))
                          (ADVP (ADV selectively))
                          (VBP enhances)
                          (NP-OB1 (NPR IL-4)
                                  (N expression)
                                  (ADJP (ADJ relative)
                                        (PP (P to)
                                            (NP (NPR IL-2)
                                                (N expression)))))
                          (PP (P by)
                              (NP (D a)
                                  (ADJ transcriptional)
                                  (N mechanism)
                                  (RRC (VAG involving)
                                       (NP-OB1 (ADJ nuclear)
                                               (N factor)
                                               (PP (P of)
                                                   (NP (VBN activated)
                                                       (NPR T)
                                                       (NS cells)))
                                               (PRN (-LRB- -LRB-)
                                                    (N NFAT)
                                                    (-RRB- -RRB-))
                                               (NS proteins)))))))
          (. .))
  (ID 140_nonfiction_GENIA-1999;99113747,4;NE))

( (IP-MAT (PP (P As)
              (IP-PPL (VAN detected)
                      (PP (P by)
                          (NP (ADJ (FW in)
                                   (FW vivo))
                              (N footprinting)))
                      (NP-LGS *by*)))
          (CRD *)
          (, ,)
          (NP-SBJ (N priming))
          (ADVP (ADV markedly))
          (VBP increases)
          (NP-OB1 (D the)
                  (ADJ activation-dependent)
                  (N engagement)
                  (PP (P of)
                      (NP (D the)
                          (ADJP (NP (PRN (NP (NP (NPR P0))
                                             (CONJP (CONJ and)
                                                    (NP (NPR P1)))))
                                    (N NFAT))
                                (ADJ -binding))
                          (NS elements)
                          (PP (P of)
                              (NP (D the)
                                  (NPR IL-4)
                                  (N promoter))))))
          (. .))
  (ID 141_nonfiction_GENIA-1999;99113747,5;NE))

( (IP-MAT (ADVP (ADV Moreover))
          (, ,)
          (NP-SBJ (Q each)
                  (ADJ proximal)
                  (NPR P)
                  (N element))
          (BEP is)
          (ADJP (ADJ essential)
                (PP (P for)
                    (NP (ADJ optimal)
                        (NPR IL-4)
                        (N promoter)
                        (N activity))))
          (. .))
  (ID 142_nonfiction_GENIA-1999;99113747,6;NE))

( (IP-MAT (NP-SBJ (ADJP (VBN Activated)
                        (VBN primed))
                  (NPR CD4)
                  (NPR T)
                  (NS cells))
          (VP (VP (VBP contain)
                  (NP-OB1 (QR more)
                          (N NFAT1)
                          (PP *ICH*-1)))
              (CONJP (CONJ and)
                     (VP (VBP support)
                         (ADJP (ADJR greater)
                               (NP (ADJ NFAT-directed)
                                   (N transcription)))))
              (PP-1 (P than)
                    (NP (ADJ unprimed)
                        (NPR CD4)
                        (NPR T)
                        (NS cells))))
          (, ,)
          (PP (P while)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (NP (N activator)
                                          (N protein)
                                          (N 1)
                                          (N binding))
                                      (CONJP (CONJ and)
                                             (NP (N activator)
                                                 (N protein)
                                                 (N 1-mediated)
                                                 (N transcription)))
                                      (PP (P by)
                                          (NP (Q both)
                                              (N cell)
                                              (NS types))))
                              (BEP is)
                              (ADJP (ADJ similar)))))
          (CRD *)
          (. .))
  (ID 143_nonfiction_GENIA-1999;99113747,7;NE))

( (IP-MAT (NP-SBJ (VBN Increased)
                  (N expression)
                  (PP (P of)
                      (NP (ADJ wild-type)
                          (N NFAT1))))
          (ADVP (ADV substantially))
          (VBP increases)
          (NP-OB1 (NPR IL-4)
                  (N promoter)
                  (N activity))
          (PP (P in)
              (NP (ADJ unprimed)
                  (NPR CD4)
                  (NPR T)
                  (NS cells)))
          (, ,)
          (IP-PPL (VAG suggesting)
                  (CP-THT (C 0)
                          (IP-SUB (NP-SBJ (N NFAT1))
                                  (MD may)
                                  (BE be)
                                  (VAG limiting)
                                  (PP (P for)
                                      (NP (NPR IL-4)
                                          (N gene)
                                          (N expression)
                                          (PP (P in)
                                              (NP (D this)
                                                  (N cell)
                                                  (N type))))))))
          (. .))
  (ID 144_nonfiction_GENIA-1999;99113747,8;NE))

( (IP-MAT (ADVP (ADV Furthermore))
          (, ,)
          (NP-SBJ (D a)
                  (ADJ truncated)
                  (N form)
                  (PP (P of)
                      (NP (N NFAT1))))
          (VBP acts)
          (PP (P as)
              (NP (D a)
                  (ADJ dominant-negative)))
          (, ,)
          (IP-PPL (IP-PPL (VAG reducing)
                          (NP-OB1 (NPR IL-4)
                                  (N promoter)
                                  (N activity))
                          (PP (P in)
                              (NP (VBN primed)
                                  (NPR CD4)
                                  (NPR T)
                                  (NS cells))))
                  (CONJP (CONJ and)
                         (IP-PPL (VAG confirming)
                                 (NP-OB1 (D the)
                                         (N importance)
                                         (PP (P of)
                                             (NP (ADJ endogenous)
                                                 (N NFAT)))
                                         (PP (P to)
                                             (NP (VAN increased)
                                                 (NPR IL-4)
                                                 (N gene)
                                                 (N expression)
                                                 (PP (P by)
                                                     (NP (N effector)
                                                         (NPR T)
                                                         (NS cells)))))))))
          (. .))
  (ID 145_nonfiction_GENIA-1999;99113747,9;NE))

( (IP-MAT (NP-SBJ (N NFAT1))
          (VBP appears)
          (ACT *__raising__*)
          (IP-INF (TO to)
                  (BE be)
                  (NP-OB1 (D the)
                          (ADJ major)
                          (NPR NFAT)
                          (N family)
                          (N member)
                          (ADJP (ADJ responsible)
                                (PP (P for)
                                    (NP (D the)
                                        (ADJ initial)
                                        (VBN increased)
                                        (N expression)
                                        (PP (P of)
                                            (NP (NPR IL-4)))
                                        (PP (P by)
                                            (NP (VBN primed)
                                                (NPR CD4)
                                                (NPR T)
                                                (NS cells))))))))
          (. .))
  (ID 146_nonfiction_GENIA-1999;99113747,10;NE))

( (FRAG (NP (ADJP (ADJ Anoxia/reoxygenation-induced))
            (N tolerance)
            (PP (P with)
                (NP (N respect)
                    (PP (P to)
                        (NP (ADJ polymorphonuclear)
                            (N leukocyte)
                            (N adhesion)
                            (PP (P to)
                                (NP (VBN cultured)
                                    (ADJ endothelial)
                                    (NS cells))))))))
        (. .))
  (ID 147_nonfiction_GENIA-1999;99115412,1;NE))

( (FRAG (NP (D A)
            (ADJP (NP (ADJ nuclear)
                      (N factor)
                      (N -kappaB))
                  (ADJ -mediated))
            (N phenomenon))
        (. .))
  (ID 148_nonfiction_GENIA-1999;99115412,2;NE))

( (IP-MAT (IP-PPL-SBJ (VAG Exposing)
                      (NP-OB1 (ADJ human)
                              (ADJ umbilical)
                              (N vein)
                              (ADJ endothelial)
                              (NS cells)
                              (PRN (-LRB- -LRB-)
                                   (NS HUVECs)
                                   (-RRB- -RRB-)))
                      (PP (P to)
                          (NP (NPR anoxia/reoxygenation)
                              (PRN (-LRB- -LRB-)
                                   (NPR A/R)
                                   (-RRB- -RRB-)))))
          (VBP results)
          (PP (P in)
              (NP (D an)
                  (N increase)
                  (PP (P in)
                      (NP (ADJ polymorphonuclear)
                          (N leukocyte)
                          (PRN (-LRB- -LRB-)
                               (NS PMN)
                               (-RRB- -RRB-))
                          (N adhesion)
                          (PP (P to)
                              (NP (NS HUVECs)))))))
          (. .))
  (ID 149_nonfiction_GENIA-1999;99115412,3;NE))

( (IP-MAT (NP-SBJ (D This)
                  (ADJ A/R-induced)
                  (N hyperadhesion))
          (BEP is)
          (ADVP (ADV completely))
          (VAN prevented)
          (PP (P by)
              (NP (D a)
                  (ADJ previous)
                  (ADVP-TMP (-LRB- -LRB-)
                            (NP-TMP (NUM 24)
                                    (NS hours))
                            (ADVR earlier)
                            (-RRB- -RRB-))
                  (N exposure)
                  (PP (P of)
                      (NP (NS HUVECs)))
                  (PP (P to)
                      (NP (NPR A/R)))))
          (NP-LGS *by*)
          (. .))
  (ID 150_nonfiction_GENIA-1999;99115412,4;NE))

( (IP-MAT (NP-SBJ (D This)
                  (N phenomenon))
          (HVP has)
          (BEN been)
          (VAN termed)
          (" ")
          (NP-OB1 (NPR A/R)
                  (N tolerance))
          (. .)
          (" "))
  (ID 151_nonfiction_GENIA-1999;99115412,5;NE))

( (IP-MAT (IP-PPL-SBJ (VAG Exposing)
                      (NP-OB1 (NS HUVECs))
                      (PP (P to)
                          (NP (NPR A/R))))
          (VBP induces)
          (NP-OB1 (D an)
                  (N increase)
                  (PP (P in)
                      (NP (ADJ nuclear)
                          (N factor)
                          (N kappaB)
                          (PRN (-LRB- -LRB-)
                               (NPR NF-kappaB)
                               (-RRB- -RRB-))))
                  (PP (P in)
                      (NP (N HUVEC)
                          (NS nuclei))))
          (PP (P within)
              (NP (NUM 4)
                  (NS hours)))
          (. .))
  (ID 152_nonfiction_GENIA-1999;99115412,6;NE))

( (IP-MAT (IP-PPL-SBJ (VAG Interfering)
                      (PP (P with)
                          (NP (CONJ either)
                              (NP (NPR NF-kappaB)
                                  (N activation)
                                  (PRN (-LRB- -LRB-)
                                       (N proteasome)
                                       (N inhibitor)
                                       (-RRB- -RRB-)))
                              (CONJP (CONJ or)
                                     (NP (N translocation)
                                         (PRN (-LRB- -LRB-)
                                              (ADJ double-stranded)
                                              (NS oligonucleotides)
                                              (RRC (VAG containing)
                                                   (NP-OB1 (NPR NF-kappaB)
                                                           (N binding)
                                                           (N sequence)))
                                              (-RRB- -RRB-)))))))
          (VBP prevents)
          (NP-OB1 (D the)
                  (N development)
                  (PP (P of)
                      (NP (NPR A/R)
                          (N tolerance)))))
  (ID 153_nonfiction_GENIA-1999;99115412,7;NE))

( (IP-MAT (-LRB- -LRB-)
          (FW ie)
          (, ,)
          (NP-SBJ (D the)
                  (N increase)
                  (PP (P in)
                      (NP (ADJP (ADJ A/R-induced))
                          (NS PMN)
                          (N adhesion)
                          (PP (P to)
                              (NP (NS HUVECs))))))
          (BEP is)
          (NP-OB1 (D the)
                  (ADJ same)
                  (PP (P after)
                      (NP (D the)
                          (NML (NP (ADJ first))
                               (CONJP (CONJ and)
                                      (NP (ADJ second)
                                          (NPR A/R)
                                          (COPY *)
                                          (NS challenges)
                                          (COPY *)))))))
          (-RRB- -RRB-)
          (. .))
  (ID 154_nonfiction_GENIA-1999;99115412,7;NE))

( (IP-MAT (NP-SBJ (N NO)
                  (N production)
                  (PP (P by)
                      (NP (NS HUVECs))))
          (BEP is)
          (VBN increased)
          (PP (PP (P after)
                  (NP (D the)
                      (ADJ second)
                      (NPR A/R)
                      (N challenge)))
              (, ,)
              (CONJP (CONJ but)
                     (PP (NEG not)
                         (P after)
                         (NP (D the)
                             (ADJ first)
                             (NPR A/R)
                             (N challenge)))))
          (. .))
  (ID 155_nonfiction_GENIA-1999;99115412,8;NE))

( (IP-MAT (NP-SBJ (N Inhibition)
                  (PP (P of)
                      (NP (N NO)
                          (N synthase)
                          (PRN (-LRB- -LRB-)
                               (N NOS)
                               (-RRB- -RRB-))))
                  (PP (P during)
                      (NP (D the)
                          (ADJ second)
                          (NPR A/R)
                          (N challenge))))
          (VBP prevents)
          (NP-OB1 (D the)
                  (N development)
                  (PP (P of)
                      (NP (NPR A/R)
                          (N tolerance))))
          (PP (P with)
              (NP (N respect)
                  (PP (P to)
                      (NP (N PMN)
                          (N adhesion)))))
          (. .))
  (ID 156_nonfiction_GENIA-1999;99115412,9;NE))

( (IP-MAT (ADVP (ADV However))
          (, ,)
          (PP (P while)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (NS HUVECs))
                              (VBD contained)
                              (NP-OB1 (ADJ endothelial)
                                      (N NOS)
                                      (N protein)))))
          (CRD *)
          (, ,)
          (NP-SBJ (Q no)
                  (ADJ inducible)
                  (N NOS))
          (BED was)
          (VAN detected)
          (PP (P in)
              (NP (CONJ either)
                  (NP (ADJ tolerant))
                  (CONJP (CONJ or)
                         (NP (ADJ nontolerant)
                             (NS cells)
                             (COPY *)))))
          (. .))
  (ID 157_nonfiction_GENIA-1999;99115412,10;NE))

( (IP-MAT (NP-SBJ (ADJ Further)
                  (NS studies))
          (VBD indicated)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (N inhibition)
                                  (PP (P of)
                                      (NP (NPR GTP-cyclohydrolase)
                                          (NPR I)
                                          (PRN (-LRB- -LRB-)
                                               (D an)
                                               (N enzyme)
                                               (RRC (VAN involved)
                                                    (PP (P in)
                                                        (NP (ADJP (FW de)
                                                                  (FW novo))
                                                            (N synthesis)
                                                            (PP (P of)
                                                                (NP (PRN (D an)
                                                                         (ADJ important)
                                                                         (N cofactor)
                                                                         (PP (P for)
                                                                             (NP (N NOS)
                                                                                 (N activity))))
                                                                    (, ,)
                                                                    (NPR tetrahydrobiopterin))))))
                                               (-RRB- -RRB-)))))
                          (VBD prevented)
                          (NP-OB1 (D the)
                                  (N generation)
                                  (PP (P of)
                                      (NP (N NO)))
                                  (PP (P in)
                                      (NP (ADJP (ADJ A/R-tolerant))
                                          (NS cells))))))
          (. .))
  (ID 158_nonfiction_GENIA-1999;99115412,11;NE))

( (IP-MAT (NP-SBJ (ADJ Extracellular)
                  (N generation)
                  (PP (P of)
                      (NP (N NO)
                          (PRN (-LRB- -LRB-)
                               (N NO)
                               (N donor)
                               (-RRB- -RRB-)))))
          (DOD did)
          (NEG not)
          (VB effect)
          (NP-OB1 (D the)
                  (N hyperadhesion)
                  (N response)
                  (RRC (VBN induced)
                       (PP (P by)
                           (NP (D the)
                               (ADJ initial)
                               (NPR A/R)
                               (N challenge)))))
          (. .))
  (ID 159_nonfiction_GENIA-1999;99115412,12;NE))

( (IP-MAT (NP-SBJ (NPR A/R))
          (ADVP (ADV also))
          (VBD induced)
          (NP-OB1 (D an)
                  (ADJ oxidant)
                  (N stress))
          (PP (PP (P in)
                  (NP (ADJ naive)
                      (NS HUVECs)))
              (, ,)
              (CONJP (CONJ but)
                     (PP (NEG not)
                         (P in)
                         (NP (ADJP (ADJ A/R-tolerant))
                             (NS HUVECs)))))
          (. .))
  (ID 160_nonfiction_GENIA-1999;99115412,13;NE))

( (IP-MAT (NP-SBJ (N Inhibition)
                  (PP (P of)
                      (NP (N NOS)))
                  (PP (P during)
                      (NP (D the)
                          (ADJ second)
                          (NPR A/R)
                          (N insult))))
          (VBP results)
          (PP (P in)
              (NP (D the)
                  (N generation)
                  (PP (P of)
                      (NP (D an)
                          (ADJ oxidant)
                          (N stress)
                          (ADJP (ADJ similar)
                                (PP (P to)
                                    (NP (D that)
                                        (RRC (VBN observed)
                                             (PP (P after)
                                                 (NP (D the)
                                                     (ADJ first)
                                                     (NPR A/R)
                                                     (N challenge)))))))))))
          (. .))
  (ID 161_nonfiction_GENIA-1999;99115412,14;NE))

( (IP-MAT (IP-PPL (VBN Taken)
                  (ADVP (ADV together)))
          (, ,)
          (NP-SBJ (D the)
                  (NS findings)
                  (PP (P of)
                      (NP (D the)
                          (ADJ present)
                          (N study))))
          (BEP are)
          (ADJP (ADJ consistent)
                (PP (P with)
                    (NP (D a)
                        (N role)
                        (PP (P for)
                            (NP (NPR NF-kappaB)))
                        (PP (P in)
                            (NP (D the)
                                (N development)
                                (PP (P of)
                                    (NP (NPR A/R)
                                        (N tolerance)
                                        (PP (-LRB- -LRB-)
                                            (P with)
                                            (NP (N respect)
                                                (PP (P to)
                                                    (NP (N PMN)
                                                        (N adhesion))))
                                            (-RRB- -RRB-))
                                        (, ,)
                                        (PP (ADV perhaps)
                                            (P by)
                                            (NP (ADJ transcriptional)
                                                (N regulation)
                                                (PP (P of)
                                                    (NP (NPR GTP-cyclohydrolase))))))))))))
          (. .))
  (ID 162_nonfiction_GENIA-1999;99115412,15;NE))

( (IP-MAT (NP-SBJ (D The)
                  (VBN increased)
                  (N NO)
                  (N production)
                  (PP (P during)
                      (NP (D the)
                          (ADJ second)
                          (NPR A/R)
                          (N insult))))
          (VBP reduces)
          (NP-OB1 (N PMN)
                  (N adhesion))
          (ADVP (QS most)
                (ADV likely)
                (PP (P by)
                    (IP-PPL (VAG reducing)
                            (NP-OB1 (D the)
                                    (ADJ intracellular)
                                    (ADJ oxidant)
                                    (N stress)
                                    (RRC (VBN induced)
                                         (PP (P by)
                                             (NP (NPR A/R))))))))
          (. .))
  (ID 163_nonfiction_GENIA-1999;99115412,16;NE))

( (FRAG (NP (N Involvement)
            (PP (P of)
                (NP (ADJ mitogen-activated)
                    (N protein)
                    (N kinase)
                    (NS pathways)))
            (PP (P in)
                (NP (NPR interleukin-8)
                    (N production)
                    (PP (P by)
                        (NP (NP (ADJ human)
                                (NS monocytes))
                            (CONJP (CONJ and)
                                   (NP (ADJ polymorphonuclear)
                                       (NS cells)
                                       (RRC (VAN stimulated)
                                            (PP (P with)
                                                (NP (NP (N lipopolysaccharide))
                                                    (CONJP (CONJ or)
                                                           (NP (N Mycoplasma)
                                                               (NS fermentans)
                                                               (N membrane)
                                                               (NS lipoproteins)))))))))))))
        (. .))
  (ID 164_nonfiction_GENIA-1999;99115544,1;NE))

( (IP-MAT (NP-SBJ (NPR Interleukin-8)
                  (PRN (-LRB- -LRB-)
                       (NPR IL-8)
                       (-RRB- -RRB-)))
          (VP (VP (BEP is)
                  (NP-OB1 (D a)
                          (N chemokine)
                          (CP-REL (WNP-1 0)
                                  (C that)
                                  (IP-SUB (NP-SBJ *T*-1)
                                          (VBP belongs)
                                          (PP (P to)
                                              (NP (D the)
                                                  (NML (NP (N alpha-chemokine))
                                                       (CONJP (CONJ or)
                                                              (NP (N CXC)
                                                                  (N subfamily)
                                                                  (COPY *))))))))))
              (CONJP (CONJ and)
                     (VP (BEP is)
                         (VAN produced)
                         (PP (P by)
                             (NP (D a)
                                 (ADJ wide)
                                 (N variety)
                                 (PP (P of)
                                     (NP (ADJ human)
                                         (NS cells)
                                         (, ,)
                                         (RRC (VAG including)
                                              (NP-OB1 (NP (NS monocytes))
                                                      (CONJP (CONJ and)
                                                             (NP (ADJ polymorphonuclear)
                                                                 (NS cells)
                                                                 (PRN (-LRB- -LRB-)
                                                                      (NS PMN)
                                                                      (-RRB- -RRB-))))))))))
                         (NP-LGS *by*))))
          (. .))
  (ID 165_nonfiction_GENIA-1999;99115544,2;NE))

( (IP-MAT (NP-SBJ (NPR IL-8))
          (BEP is)
          (VBN secreted)
          (PP (P in)
              (NP (N response)
                  (PP (P to)
                      (NP (ADJ inflammatory)
                          (NS stimuli)
                          (, ,)
                          (PRN (ADVP (ADV notably))
                               (ADJ bacterial)
                               (NS products)
                               (ADJP (ADJ such)
                                     (PP (P as)
                                         (NP (NPR lipopolysaccharide)
                                             (PRN (-LRB- -LRB-)
                                                  (NPR LPS)
                                                  (-RRB- -RRB-))))))))))
          (, ,))
  (ID 166_nonfiction_GENIA-1999;99115544,3;NE))

( (IP-MAT (CONJ but)
          (NP-SBJ (Q little))
          (BEP is)
          (VAN known)
          (PP (P about)
              (NP (D the)
                  (NS mechanisms)
                  (CP-REL (WPP-1 (P by)
                                 (WNP (WPRO which)))
                          (C 0)
                          (IP-SUB (PP *T*-1)
                                  (NP-SBJ (D these)
                                          (NS agents))
                                  (VBP mediate)
                                  (NP-OB1 (NPR IL-8)
                                          (N induction))))))
          (. .))
  (ID 167_nonfiction_GENIA-1999;99115544,3;NE))

( (IP-MAT (PP (P In)
              (NP (D this)
                  (N report)))
          (, ,)
          (NP-SBJ (PRO we))
          (VBP show)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (N Mycoplasma)
                                  (NS fermentans)
                                  (ADJ lipid-associated)
                                  (N membrane)
                                  (NS proteins)
                                  (PRN (-LRB- -LRB-)
                                       (NPR LAMPf)
                                       (-RRB- -RRB-)))
                          (VBP induce)
                          (NP-OB1 (D the)
                                  (N production)
                                  (PP (P of)
                                      (NP (ADJ high)
                                          (NS levels)
                                          (PP (P of)
                                              (NP (NPR IL-8)))))
                                  (PP (P by)
                                      (NP (NP (NPR THP-1)
                                              (PRN (-LRB- -LRB-)
                                                   (ADJ human)
                                                   (N monocyte)
                                                   (-RRB- -RRB-))
                                              (NS cells))
                                          (CONJP (CONJ and)
                                                 (NP (NS PMN))))))
                          (PP (P at)
                              (NP (D the)
                                  (ADJ same)
                                  (N extent)
                                  (PP (P as)
                                      (NP (NPR LPS)))))))
          (. .))
  (ID 168_nonfiction_GENIA-1999;99115544,4;NE))

( (IP-MAT (NP-SBJ-1 (PRO It))
          (BED was)
          (ADVP-TMP (ADV previously))
          (VAN demonstrated)
          (CP-THT-1 (C that)
                    (IP-SUB (NP-SBJ (N stimulation)
                                    (PP (P of)
                                        (NP (ADJ monocytic)
                                            (NS cells)))
                                    (PP (P with)
                                        (NP (CONJ either)
                                            (NP (NPR LPS))
                                            (CONJP (CONJ or)
                                                   (NP (NPR LAMPf))))))
                            (VBD led)
                            (PP (P to)
                                (NP (D a)
                                    (N series)
                                    (PP (P of)
                                        (NP (ADJ common)
                                            (ADJ downstream)
                                            (ADJ signaling)
                                            (NS events)
                                            (, ,)
                                            (RRC (VAG including)
                                                 (NP-OB1 (D the)
                                                         (N activation)
                                                         (PP (PP (P of)
                                                                 (NP (N protein)
                                                                     (N tyrosine)
                                                                     (N kinase)))
                                                             (CONJP (CONJ and)
                                                                    (PP (P of)
                                                                        (NP (ADJ mitogen-activated)
                                                                            (N protein)
                                                                            (N kinase)
                                                                            (NS cascades)))))))))))))
          (. .))
  (ID 169_nonfiction_GENIA-1999;99115544,5;NE))

( (IP-MAT (PP (P By)
              (IP-PPL (VAG using)
                      (NP-OB1 (NML (NP (NPR PD-98059))
                                   (CONJP (CONJ and)
                                          (NP (NPR SB203580))))
                              (, ,)
                              (PRN (NUM two)
                                   (ADJP (ADJP (ADJ potent))
                                         (CONJP (CONJ and)
                                                (ADJP (ADJ selective))))
                                   (NS inhibitors)
                                   (PP (P of)
                                       (NP (NP (NPR MEK1)
                                               (PRN (-LRB- -LRB-)
                                                    (D a)
                                                    (N kinase)
                                                    (ADVP-LOC (ADV upstream)
                                                              (PP (P of)
                                                                  (NP (NPR ERK1/2))))
                                                    (-RRB- -RRB-)))
                                           (CONJP (CONJ and)
                                                  (NP (NPR p38)))))))
                      (, ,)
                      (ADVP (ADV respectively))))
          (, ,)
          (NP-SBJ (PRO we))
          (HVP have)
          (VBN demonstrated)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (BIND *group*)
                                  (Q both)
                                  (NML (NP (NPR ERK1/2))
                                       (CONJP (CONJ and)
                                              (NP (NPR p38))))
                                  (NS cascades))
                          (VBP play)
                          (NP-OB1 (D a)
                                  (ADJ key)
                                  (N role)
                                  (PP (P in)
                                      (NP (D the)
                                          (N production)
                                          (PP (P of)
                                              (NP (NPR IL-8)))
                                          (PP (P by)
                                              (NP (NML (NP (NS monocytes))
                                                       (CONJP (CONJ and)
                                                              (NP (NS PMN))))
                                                  (RRC (VAN stimulated)
                                                       (PP (P with)
                                                           (NP (ADJ bacterial)
                                                               (NS fractions)))))))))))
          (. .))
  (ID 170_nonfiction_GENIA-1999;99115544,6;NE))

( (IP-MAT (NP-SBJ (NP (NPR CD80))
                  (CONJP (CONJ and)
                         (NP (NPR CD86))))
          (BEP are)
          (NEG not)
          (ADJP (ADJ equivalent)
                (PP (P in)
                    (NP (NP-POS (PRO their))
                        (N ability)
                        (IP-INF (TO to)
                                (VB induce)
                                (NP-OB1 (D the)
                                        (N tyrosine)
                                        (N phosphorylation)
                                        (PP (P of)
                                            (NP (NPR CD28))))))))
          (. .))
  (ID 171_nonfiction_GENIA-1999;99115659,1;NE))

( (IP-MAT (NP-SBJ (N Ligation)
                  (PP (P of)
                      (NP (NML (CONJ either)
                               (NP (NPR CD80)
                                   (PRN (-LRB- -LRB-)
                                        (NPR B7-1)
                                        (-RRB- -RRB-)))
                               (CONJP (CONJ or)
                                      (NP (NPR CD86)
                                          (PRN (-LRB- -LRB-)
                                               (NPR B7-2)
                                               (-RRB- -RRB-)))))
                          (, ,)
                          (PRN (NUM two)
                               (ADJ principal)
                               (NS ligands)
                               (PP (P for)
                                   (NP (NPR CD28)))))))
          (, ,)
          (BEP is)
          (VAN thought)
          (IP-INF (TO to)
                  (VB skew)
                  (NP-OB1 (D the)
                          (ADJ immune)
                          (N response)
                          (PP (P toward)
                              (NP (PRN (NP (NP (NPR Th1))
                                           (CONJP (CONJ or)
                                                  (NP (NPR Th2)))))
                                  (N differentiation)))))
          (. .))
  (ID 172_nonfiction_GENIA-1999;99115659,2;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (HVP have)
          (VBN examined)
          (NP-OB1 (ADJ early)
                  (N signal)
                  (N transduction)
                  (NS pathways)
                  (RRC (VAN recruited))
                  (RRC (VAG following)
                       (NP-OB1 (NPR T)
                               (N cell)
                               (N stimulation)
                               (PP (P with)
                                   (NP (CONJ either)
                                       (NP (NPR CD80))
                                       (CONJP (CONJ or)
                                              (NP (NPR CD86))))))))
          (. .))
  (ID 173_nonfiction_GENIA-1999;99115659,3;NE))

( (IP-MAT (NP-SBJ (NP (VBN Purified)
                      (ADJP (ADJ human)
                            (ADJ peripheral))
                      (NPR T)
                      (NS cells))
                  (CONJP (CONJ or)
                         (NP (NPR Jurkat)
                             (NPR T)
                             (NS cells))))
          (BED were)
          (VAN stimulated)
          (PP (PP (P with)
                  (NP (ADJ Chinese)
                      (N hamster)
                      (N ovary)
                      (PRN (-LRB- -LRB-)
                           (N CHO)
                           (-RRB- -RRB-))
                      (NS cells)
                      (RRC (VAG expressing)
                           (NP-OB1 (CONJ either)
                                   (NP (ADJ human)
                                       (NPR CD80)
                                       (PRN (-LRB- -LRB-)
                                            (NPR CHO-CD80)
                                            (-RRB- -RRB-)))
                                   (CONJP (CONJ or)
                                          (NP (ADJ human)
                                              (NPR CD86)
                                              (PRN (-LRB- -LRB-)
                                                   (NPR CHO-CD86)
                                                   (-RRB- -RRB-))))))))
              (CONJP (CONJ or)
                     (PP (P with)
                         (NP (ADJ anti-CD28)
                             (ADJ monoclonal)
                             (N antibody)
                             (PRN (-LRB- -LRB-)
                                  (N mAb)
                                  (-RRB- -RRB-))))))
          (. .))
  (ID 174_nonfiction_GENIA-1999;99115659,4;NE))

( (IP-MAT (PP (P In)
              (NP (D the)
                  (N presence)
                  (PP (P of)
                      (NP (N phorbol)
                          (N 12-myristate)
                          (N 13-acetate)))))
          (, ,)
          (NP-SBJ (BIND *group*)
                  (Q both)
                  (NML (NP (NPR CHO-CD80))
                       (CONJP (CONJ and)
                              (NP (NPR CHO-CD86)))))
          (, ,)
          (ADJP-SPR (ADJ like)
                    (NP (ADJ anti-CD28)
                        (N mAb)))
          (, ,)
          (BED were)
          (ADJP (ADJ capable)
                (PP (P of)
                    (IP-PPL (VAG stimulating)
                            (NP-OB1 (N cytokine)
                                    (N production))
                            (PP (P from)
                                (NP (BIND *group*)
                                    (Q both)
                                    (NML (NP (ADJ human)
                                             (ADJ peripheral)
                                             (NPR T)
                                             (NS cells))
                                         (CONJP (CONJ and)
                                                (NP (NPR Jurkat)
                                                    (NPR T)
                                                    (NS cells)))))))))
          (. .))
  (ID 175_nonfiction_GENIA-1999;99115659,5;NE))

( (IP-MAT (NP-SBJ (CONJ Both)
                  (NP (NPR CHO-CD80))
                  (CONJP (CONJ and)
                         (NP (N CHO-CD86))))
          (, ,)
          (PP (P in)
              (NP (D the)
                  (N presence)
                  (PP (P of)
                      (NP (ADJ anti-CD3)
                          (N mAb)))))
          (, ,)
          (VBD costimulated)
          (NP-OB1 (ADJ NFAT-dependent)
                  (ADJ transcriptional)
                  (N activation))
          (. .))
  (ID 176_nonfiction_GENIA-1999;99115659,6;NE))

( (IP-MAT (NP-SBJ (Q Several)
                  (ADJ intracellular)
                  (VAG signaling)
                  (NS proteins)
                  (, ,)
                  (ADJP (ADJ such)
                        (PP (P as)
                            (NP (NP (NPR CBL))
                                (CONJP (CONJ and)
                                       (NP (NPR VAV)))))))
          (, ,)
          (BED were)
          (VBN phosphorylated)
          (PP (P on)
              (NP (N tyrosine)))
          (PP (P in)
              (NP (N response)
                  (PP (P to)
                      (NP (NP (NPR CD80))
                          (, ,)
                          (CONJP (NP (NPR CD86)))
                          (, ,)
                          (CONJP (CONJ and)
                                 (NP (ADJ anti-CD28)
                                     (N mAb)))))))
          (. .))
  (ID 177_nonfiction_GENIA-1999;99115659,7;NE))

( (IP-MAT (ADVP (ADV Surprisingly))
          (, ,)
          (PP (P although)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (N stimulation)
                                      (PP (P of)
                                          (NP (NPR Jurkat)
                                              (NPR T)
                                              (NS cells)))
                                      (PP (P with)
                                          (NP (CONJ either)
                                              (NP (NPR CHO-CD80))
                                              (CONJP (CONJ or)
                                                     (NP (ADJ anti-CD28)
                                                         (N mAb))))))
                              (VBD resulted)
                              (PP (P in)
                                  (NP (ADJ robust)
                                      (N tyrosine)
                                      (N phosphorylation)
                                      (PP (P of)
                                          (NP (NPR CD28)
                                              (NP-RFL (PRO itself)))))))))
          (, ,)
          (NP-SBJ (N ligation)
                  (PP (P with)
                      (NP (NPR CHO-CD86))))
          (BED was)
          (ADJP (ADJ unable)
                (IP-INF (TO to)
                        (VB induce)
                        (NP-OB1 (ADJ detectable)
                                (NPR CD28)
                                (N tyrosyl)
                                (N phosphorylation))
                        (PP (P over)
                            (NP (D a)
                                (N range)
                                (PP (P of)
                                    (NP (N stimulation)
                                        (NS conditions)))))))
          (. .))
  (ID 178_nonfiction_GENIA-1999;99115659,8;NE))

( (IP-MAT (PP (P In)
              (NP (N addition)))
          (, ,)
          (NP-SBJ (D the)
                  (N association)
                  (PP (P of)
                      (NP (NPR phosphoinositide)
                          (NPR 3-kinase)))
                  (PP (P with)
                      (NML (NP (NPR CD28))
                           (CONJP (CONJ and)
                                  (NP (ADJ enhanced)
                                      (N tyrosine)
                                      (N phosphorylation)
                                      (PP (P of)
                                          (NP (NPR phospholipase)
                                              (NPR Cgamma))))))))
          (VP (VP (BED were)
                  (COPY *)
                  (VAN seen)
                  (COPY *)
                  (PP (P after)
                      (NP (PRN (NP (NP (ADJ anti-CD28)
                                       (N mAb))
                                   (CONJP (CONJ and)
                                          (NP (NPR CHO-CD80)))))
                          (N stimulation))))
              (CONJP (CONJ but)
                     (VP (PP (P to)
                             (NP (D a)
                                 (ADJP (Q much)
                                       (ADJR lesser))
                                 (N extent)))
                         (PP (P after)
                             (NP (NPR CHO-CD86)
                                 (N stimulation))))))
          (. .))
  (ID 179_nonfiction_GENIA-1999;99115659,9;NE))

( (IP-MAT (ADVP (ADV Thus))
          (, ,)
          (NP-SBJ (N ligation)
                  (PP (P of)
                      (NP (NPR CD28)))
                  (PP (P with)
                      (NP (CONJ either)
                          (NP (NPR CD80))
                          (CONJP (CONJ or)
                                 (NP (NPR CD86))))))
          (VBP leads)
          (PP (PP (P to)
                  (NP (ADJ shared)
                      (ADJ early)
                      (N signal)
                      (N transduction)
                      (NS events)
                      (ADJP (ADJ such)
                            (PP (P as)
                                (NP (D the)
                                    (N tyrosine)
                                    (N phosphorylation)
                                    (PP (P of)
                                        (NP (NP (NPR CBL))
                                            (CONJP (CONJ and)
                                                   (NP (NPR VAV))))))))))
              (, ,)
              (CONJP (PP (P to)
                         (NP (ADJ NFAT-mediated)
                             (ADJ transcriptional)
                             (N activation))))
              (, ,)
              (CONJP (CONJ and)
                     (PP (P to)
                         (NP (D the)
                             (N costimulation)
                             (PP (P of)
                                 (NP (ADJP (NP (NP (NPR interleukin-2))
                                               (CONJP (CONJ and)
                                                      (NP (NPR granulocyte-macrophage))))
                                           (ADJ colony-stimulating))
                                     (N factor)
                                     (N production)))))))
          (. .))
  (ID 180_nonfiction_GENIA-1999;99115659,10;NE))

( (IP-MAT (ADVP (ADV However))
          (, ,)
          (NP-SBJ (NP (NPR CD80))
                  (CONJP (CONJ and)
                         (NP (NPR CD86))))
          (ADVP (ADV also))
          (VBP induce)
          (NP-OB1 (ADJ distinct)
                  (N signal)
                  (N transduction)
                  (NS pathways)
                  (RRC (VAG including)
                       (NP-OB1 (NP (D the)
                                   (N tyrosine)
                                   (N phosphorylation)
                                   (PP (P of)
                                       (NP (NP (NPR CD28))
                                           (CONJP (CONJ and)
                                                  (NP (NPR phospholipase)
                                                      (NPR Cgamma1))))))
                               (CONJP (CONJ and)
                                      (NP (D the)
                                          (ADJP (ADJ SH2-dependent))
                                          (N association)
                                          (PP (P of)
                                              (NP (NPR phosphoinositide)
                                                  (NPR 3-kinase)))
                                          (PP (P with)
                                              (NP (NPR CD28))))))))
          (. .))
  (ID 181_nonfiction_GENIA-1999;99115659,11;NE))

( (IP-MAT (NP-SBJ (D These)
                  (ADJP (ADJ quantitative)
                        (, ,)
                        (PP (P if)
                            (NEG not)
                            (ADJP (ADJ qualitative))))
                  (, ,)
                  (NS differences)
                  (PP (P between)
                      (NP (N signaling)
                          (RRC (VAN initiated)
                               (PP (P by)
                                   (NP (D these)
                                       (NUM two)
                                       (NS ligands)))
                               (NP-LGS *by*)
                               (PP (P for)
                                   (NP (NPR CD28)))))))
          (MD may)
          (VB contribute)
          (PP (P to)
              (NP (ADJ functional)
                  (NS differences)
                  (PP (-LRB- -LRB-)
                      (FW e.g.)
                      (NP (PRN (NP (NP (NPR Th1))
                                   (CONJP (CONJ or)
                                          (NP (NPR Th2)))))
                          (N differentiation))
                      (-RRB- -RRB-))))
          (PP (P in)
              (NP (NPR T)
                  (N cell)
                  (NS responses)))
          (. .))
  (ID 182_nonfiction_GENIA-1999;99115659,12;NE))

( (FRAG (NP (N Role)
            (PP (P of)
                (NP (NPR Egr-2)))
            (PP (P in)
                (NP (N up-regulation)
                    (PP (P of)
                        (NP (N Fas)
                            (N ligand)))
                    (PP (P in)
                        (NP (NP (ADJ normal)
                                (NPR T)
                                (NS cells))
                            (CONJP (CONJ and)
                                   (NP (PRN (NP (NP (ADJ aberrant)
                                                    (ADJ double-negative)
                                                    (N lpr))
                                                (CONJP (CONJ and)
                                                       (NP (N gld)
                                                           (NPR T)))))
                                       (NS cells))))))))
        (. .))
  (ID 183_nonfiction_GENIA-1999;99115672,1;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VP (VP (ADVP-TMP (ADV previously))
                  (VBD identified)
                  (NP-OB1 (D a)
                          (N Fas)
                          (N ligand)
                          (ADJ regulatory)
                          (N element)
                          (PRN (-LRB- -LRB-)
                               (N FLRE)
                               (-RRB- -RRB-))
                          (PP (P in)
                              (NP (D the)
                                  (N Fas)
                                  (N ligand)
                                  (PRN (-LRB- -LRB-)
                                       (N fasL)
                                       (-RRB- -RRB-))
                                  (N promoter)
                                  (CP-REL (WNP-2 0)
                                          (C that)
                                          (IP-SUB (NP-SBJ *T*-2)
                                                  (VBP binds)
                                                  (NP-OB1 (NPR Egr)
                                                          (N family)
                                                          (NS proteins))))))))
              (CONJP (CONJ and)
                     (VP (VBD demonstrated)
                         (CP-THT (C that)
                                 (IP-SUB (NP-SBJ (NP (NPR Egr-3)
                                                     (PRN (-LRB- -LRB-)
                                                          (NPR PILOT)
                                                          (-RRB- -RRB-)))
                                                 (CONJP (CONJ but)
                                                        (NP (NEG not)
                                                            (NPR Egr-1)
                                                            (PRN (NP (-LRB- -LRB-)
                                                                     (NP (NPR NGFI-A))
                                                                     (, ,)
                                                                     (CONJP (NP (NPR Krox-24)))
                                                                     (, ,)
                                                                     (CONJP (NP (NPR Tis-8)))
                                                                     (, ,)
                                                                     (CONJP (CONJ and)
                                                                            (NP (NPR Zif-268)))
                                                                     (-RRB- -RRB-))))))
                                         (VBP induces)
                                         (NP-OB1 (N transcription)
                                                 (PP (P of)
                                                     (NP (N fasL)))))))))
          (. .))
  (ID 184_nonfiction_GENIA-1999;99115672,2;NE))

( (IP-MAT (NP-SBJ (D The)
                  (ADJ aberrant)
                  (NPR CD4)
                  (NPR CD8)
                  (NPR T)
                  (NS cells)
                  (PP (P from)
                      (NP (NP (N lpr/lpr))
                          (CONJP (CONJ and)
                                 (NP (N gld/gld)
                                     (NS mice)
                                     (COPY *)))))
                  (, ,)
                  (CP-REL (WNP-1 (WPRO which))
                          (C 0)
                          (IP-SUB (NP-SBJ *T*-1)
                                  (HVP have)
                                  (NP-OB1 (NS mutations)
                                          (PP (P in)
                                              (NP (D the)
                                                  (NS genes)
                                                  (RRC (VAG encoding)
                                                       (NP-OB1 (NP (N Fas))
                                                               (CONJP (CONJ and)
                                                                      (NP (N FasL))))
                                                       (, ,)
                                                       (ADVP (ADV respectively)))))))))
          (, ,)
          (VP (VP (HVP have)
                  (NP-OB1 (D an)
                          (VBN activated)
                          (N phenotype)))
              (CONJP (CONJ and)
                     (VP (ADVP (ADV constitutively))
                         (VBP express)
                         (NP-OB1 (ADJ high)
                                 (NS levels)
                                 (PP (P of)
                                     (NP (N fasL)
                                         (N mRNA)))))))
          (, ,)
          (IP-PPL (VAG prompting)
                  (NP-OB1 (PRO us))
                  (IP-INF (TO to)
                          (VB ask)
                          (CP-QUE (WNP-2 (WD what)
                                         (N role)
                                         (PP (P if)
                                             (NP (Q any))))
                                  (C 0)
                                  (IP-SUB (NP-OB1 *T*-2)
                                          (NP-SBJ (D the)
                                                  (NML (NP (N FLRE))
                                                       (CONJP (CONJ and)
                                                              (NP (N Egr)
                                                                  (N family)
                                                                  (COPY *)
                                                                  (NS proteins)
                                                                  (COPY *)))))
                                          (HVP have)
                                          (PP (P in)
                                              (NP (D this)
                                                  (ADJ aberrant)
                                                  (N expression)
                                                  (PP (P of)
                                                      (NP (N fasL)))))))))
          (. .))
  (ID 185_nonfiction_GENIA-1999;99115672,3;NE))

( (IP-MAT (NP-SBJ (ADJ Unstimulated)
                  (PRN (NP (NP (NPR MRL-lpr/lpr))
                           (CONJP (CONJ and)
                                  (NP (NPR C3H-gld/gld)))))
                  (NPR CD4)
                  (NPR CD8)
                  (NPR T)
                  (NS cells))
          (ADVP (ADV constitutively))
          (VBD contained)
          (NP-OB1 (ADJ high)
                  (NS levels)
                  (PP (P of)
                      (NP (NUM two)
                          (NS proteins)
                          (CP-REL (WNP-1 0)
                                  (C that)
                                  (IP-SUB (NP-SBJ *T*-1)
                                          (VBD bound)
                                          (PP (P to)
                                              (NP (D the)
                                                  (N FLRE))))))))
          (. .))
  (ID 186_nonfiction_GENIA-1999;99115672,4;NE))

( (IP-MAT (NP-SBJ (N Supershift)
                  (N analysis))
          (VBD revealed)
          (NP-OB1 (D these)
                  (NS proteins))
          (IP-INF (TO to)
                  (BE be)
                  (NP-OB1 (NP (NPR Egr-1))
                          (CONJP (CONJ and)
                                 (NP (NPR Egr-2)
                                     (PRN (-LRB- -LRB-)
                                          (NPR Krox-20)
                                          (-RRB- -RRB-))))))
          (. ;))
  (ID 187_nonfiction_GENIA-1999;99115672,5;NE))

( (IP-MAT (NP-SBJ (NPR Egr-3))
          (BED was)
          (NEG not)
          (VAN detected)
          (. .))
  (ID 188_nonfiction_GENIA-1999;99115672,5;NE))

( (IP-MAT (NP-SBJ (N Activation)
                  (PP (P of)
                      (NP (ADJ normal)
                          (N lymph)
                          (N node)
                          (NS cells))))
          (VBD resulted)
          (PP (P in)
              (NP (VBN increased)
                  (N expression)
                  (PP (P of)
                      (NP (NP (NPR Egr-1))
                          (, ,)
                          (CONJP (NP (NPR -2)))
                          (, ,)
                          (CONJP (CONJ and)
                                 (NP (NPR -3)))))))
          (. .))
  (ID 189_nonfiction_GENIA-1999;99115672,6;NE))

( (IP-MAT (PP (P As)
              (PP (P with)
                  (NP (NPR egr-3))))
          (, ,)
          (NP-SBJ (N expression)
                  (PP (P of)
                      (NP (NPR egr-2))))
          (BED was)
          (VAN blocked)
          (PP (P by)
              (NP (NPR cyclosporin)
                  (NPR A)))
          (NP-LGS *by*)
          (. .))
  (ID 190_nonfiction_GENIA-1999;99115672,7;NE))

( (IP-MAT (PP (P Although)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (VBN overexpressed)
                                      (NPR Egr-1))
                              (BED was)
                              (ADJP (ADJ ineffective)))))
          (, ,)
          (NP-SBJ (VBN overexpressed)
                  (NPR Egr-2))
          (BED was)
          (ADJP (ADVR as)
                (ADJ potent)
                (PP (P as)
                    (NP (NPR Egr-3))))
          (PP (P in)
              (IP-PPL (VAG inducing)
                      (NP-OB1 (N fasL)
                              (ADJ promoter-dependent)
                              (N reporter)
                              (NS constructs))
                      (PP (P in)
                          (NP (NP (NPR T)
                                  (N cell)
                                  (NS hybridomas))
                              (CONJP (CONJ and)
                                     (NP (NPR HeLa)
                                         (NS cells)))))))
          (, ,))
  (ID 191_nonfiction_GENIA-1999;99115672,8;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (Q both))
          (VBD up-regulated)
          (NP-OB1 (ADJ endogenous)
                  (N fasL)
                  (N mRNA))
          (PP (P in)
              (NP (NPR HeLa)
                  (NS cells)))
          (. .))
  (ID 192_nonfiction_GENIA-1999;99115672,8;NE))

( (IP-MAT (NP-SBJ (ADJP (ADJ FasL-dependent))
                  (N reporter)
                  (NS constructs)
                  (PP (P in)
                      (NP (PRN (NP (NP (NPR MRL-lpr/lpr))
                                   (CONJP (CONJ and)
                                          (NP (NPR C3H-gld/gld)))))
                          (NPR CD4)
                          (NPR CD8)
                          (NPR T)
                          (NS cells))))
          (BED were)
          (ADJP (ADV constitutively)
                (ADJ active))
          (, ,))
  (ID 193_nonfiction_GENIA-1999;99115672,9;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (D this)
                  (N activity))
          (BED was)
          (ADVP (ADV largely))
          (VAN prevented)
          (PP (P by)
              (NP (N mutation)
                  (PP (P of)
                      (NP (D the)
                          (ADJ critical)
                          (N Egr)
                          (N family)
                          (N binding)
                          (N element)))))
          (NP-LGS *by*)
          (. .))
  (ID 194_nonfiction_GENIA-1999;99115672,9;NE))

( (IP-MAT (ADVP (ADV Thus))
          (, ,)
          (NP-SBJ (NPR Egr-2))
          (, ,)
          (PP (P in)
              (NP (N addition)
                  (PP (P to)
                      (NP (NPR Egr-3)))))
          (, ,)
          (VBP regulates)
          (NP-OB1 (N FasL)
                  (N expression)
                  (PP (P in)
                      (NP (VBN activated)
                          (ADJ normal)
                          (NPR T)
                          (NS cells))))
          (, ,))
  (ID 195_nonfiction_GENIA-1999;99115672,10;NE))

( (IP-MAT (CONJ and)
          (NP-SBJ (NPR Egr-2))
          (BEP is)
          (ADJP (ADJ likely)
                (IP-INF (TO to)
                        (VB play)
                        (NP-OB1 (D a)
                                (ADJ direct)
                                (N role))
                        (PP (P in)
                            (NP (N aberrant)
                                (N fasL)
                                (N up-regulation)
                                (PP (P in)
                                    (NP (PRN (NP (NP (NPR lpr/lpr))
                                                 (CONJP (CONJ and)
                                                        (NP (NPR gld/gld)))))
                                        (NPR CD4)
                                        (NPR CD8)
                                        (NPR T)
                                        (NS cells)))))))
          (. .))
  (ID 196_nonfiction_GENIA-1999;99115672,10;NE))

( (FRAG (NP (N Inhibition)
            (PP (P of)
                (NP (NPR NF-kappaB)
                    (N activation)
                    (ADJP (ADJP (FW in)
                                (FW vitro))
                          (CONJP (CONJ and)
                                 (ADJP (FW in)
                                       (FW vivo))))))
            (, :)
            (PRN (N role)
                 (PP (P of)
                     (NP (NPR 26S)
                         (N proteasome)))))
        (. .))
  (ID 197_nonfiction_GENIA-1999;99118181,1;NE))

( (IP-MAT (NP-SBJ-1 (PRO It))
          (BEP is)
          (VAG becoming)
          (ADJP (ADV increasingly)
                (ADJ apparent))
          (CP-THT-1 (C that)
                    (IP-SUB (NP-SBJ (NPR NF-kappaB))
                            (VBP plays)
                            (NP-OB1 (D a)
                                    (ADJ critical)
                                    (N role)
                                    (PP (P in)
                                        (IP-PPL (VAG regulating)
                                                (NP-OB1 (D the)
                                                        (ADJ inflammatory)
                                                        (N response)))))))
          (. .))
  (ID 198_nonfiction_GENIA-1999;99118181,2;NE))

( (IP-MAT (NP-SBJ (NS Data)
                  (RRC (VAN obtained)
                       (PP (P from)
                           (NP (NS studies)
                               (PP (P in)
                                   (NP (NP-POS (PRO our))
                                       (NS laboratories)))))))
          (VBP demonstrate)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (D the)
                                  (N proteasome))
                          (VBP plays)
                          (NP-OB1 (D an)
                                  (ADJ important)
                                  (N role)
                                  (PP (P in)
                                      (NP (D the)
                                          (ADJ inflammatory)
                                          (N cascade)))
                                  (PP (P by)
                                      (IP-PPL (VAG regulating)
                                              (NP-OB1 (D the)
                                                      (N activation)
                                                      (PP (P of)
                                                          (NP (NPR NF-kappaB)))))))))
          (. .))
  (ID 199_nonfiction_GENIA-1999;99118181,3;NE))

( (IP-MAT (PP (P+N Indeed))
          (, ,)
          (NP-SBJ (D the)
                  (N availability)
                  (PP (P of)
                      (NP (NP (ADJ selective))
                          (CONJP (CONJ and)
                                 (NP (ADJP (ADV orally)
                                           (ADJ active))
                                     (N proteasome)
                                     (COPY *)
                                     (NS inhibitors)
                                     (COPY *))))))
          (MD should)
          (VB prove)
          (ADJP (ADJ useful)
                (PP (P in)
                    (IP-PPL (VAG delineating)
                            (NP-OB1 (D the)
                                    (NS roles)
                                    (PP (P of)
                                        (NP (NP (D the)
                                                (N proteasome))
                                            (CONJP (CONJ and)
                                                   (NP (NPR NF-kappaB)))))
                                    (PP (P in)
                                        (NP (ADJ other)
                                            (ADJ pathophysiological)
                                            (NS conditions)
                                            (ADJP (ADJ such)
                                                  (PP (P as)
                                                      (NP (NP (N cancer))
                                                          (CONJP (CONJ and)
                                                                 (NP (N heart)
                                                                     (N disease))))))))))))
          (. .))
  (ID 200_nonfiction_GENIA-1999;99118181,4;NE))

( (FRAG (NP (N Requirement)
            (PP (P of)
                (NP (PRN (NP (NP (NPR GATA-1))
                             (CONJP (CONJ and)
                                    (NP (NPR p45)))))
                    (N NF-E2)
                    (N expression)
                    (PP (P in)
                        (NP (ADJP (NP (NPR butyric)
                                      (N acid))
                                  (ADJ -induced))
                            (ADJ erythroid)
                            (N differentiation))))))
        (. .))
  (ID 201_nonfiction_GENIA-1999;99119105,1;NE))

( (IP-MAT (NP-SBJ (NPR Butyric)
                  (N acid)
                  (PRN (-LRB- -LRB-)
                       (NPR BA)
                       (-RRB- -RRB-)))
          (BEP is)
          (VBN known)
          (IP-INF (TO to)
                  (VB induce)
                  (NP-OB1 (N overexpression)
                          (PP (P of)
                              (NP (NP (ADJ fetal)
                                      (N hemoglobin))
                                  (CONJP (CONJ and)
                                         (ADV then)
                                         (NP (ADJ erythroid)
                                             (N differentiation)))))))
          (. .))
  (ID 202_nonfiction_GENIA-1999;99119105,2;NE))

( (IP-MAT (ADVP (ADV Therefore))
          (, ,)
          (NP-SBJ (NPR BA))
          (BEP is)
          (ADVP-TMP (ADV currently))
          (PP (P under)
              (NP (ADJ clinical)
                  (N investigation)
                  (PP (P as)
                      (NP (D a)
                          (ADJ potential)
                          (N therapy)
                          (PP (P for)
                              (NP (D the)
                                  (N treatment)
                                  (PP (P of)
                                      (NP (NP (ADJ sickle)
                                              (N cell)
                                              (N disease))
                                          (CONJP (CONJ and)
                                                 (NP (N cancer)))))))))))
          (. .))
  (ID 203_nonfiction_GENIA-1999;99119105,3;NE))

( (IP-MAT (ADVP (ADV Nevertheless))
          (, ,)
          (NP-SBJ (D the)
                  (ADJ molecular)
                  (NS mechanisms)
                  (RRC (VAN involved)
                       (PP (P in)
                           (NP (ADJP (ADJ BA-induced))
                               (N differentiation)))))
          (VBP remain)
          (ADJP (ADV largely)
                (ADJ unknown))
          (. .))
  (ID 204_nonfiction_GENIA-1999;99119105,4;NE))

( (IP-MAT (NP-SBJ (ADJ Previous)
                  (NS reports))
          (HVP have)
          (VBN shown)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (ADJP (ADJ BA-induced))
                                  (N overexpression)
                                  (PP (P of)
                                      (NP (ADJ erythroid)
                                          (NS genes))))
                          (VBD occurred)
                          (PP (P at)
                              (NP (D the)
                                  (ADJ transcriptional)
                                  (N level)))))
          (, ,)
          (IP-PPL (VAG suggesting)
                  (NP-OB1 (D the)
                          (N involvement)
                          (PP (P of)
                              (NP (ADJ erythroid)
                                  (N transcription)
                                  (NS factors)))))
          (. .))
  (ID 205_nonfiction_GENIA-1999;99119105,5;NE))

( (IP-MAT (ADVP-LOC (ADV Here))
          (, ,)
          (NP-SBJ (PRO we))
          (VBP intend)
          (IP-INF (TO to)
                  (VB demonstrate)
                  (NP-OB1 (D the)
                          (N requirement)
                          (PP (P of)
                              (NP (PRN (NP (NP (N GATA-1))
                                           (CONJP (CONJ and)
                                                  (NP (N NF-E2)))))
                                  (N transcription)
                                  (NS factors)))
                          (PP (P in)
                              (NP (D the)
                                  (ADJP (ADJ BA-induced))
                                  (ADJ erythroid)
                                  (N differentiation)
                                  (PP (P of)
                                      (NP (ADJ human)
                                          (ADJ leukemic)
                                          (NPR K562)
                                          (NS cells)))))))
          (. .))
  (ID 206_nonfiction_GENIA-1999;99119105,6;NE))

( (IP-MAT (NP-SBJ (ADJ Time-course)
                  (NS experiments))
          (VBD showed)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (ADJ nuclear)
                                  (NS levels)
                                  (PP (P of)
                                      (NP (PRN (NP (NP (NPR GATA-1))
                                                   (CONJP (CONJ and)
                                                          (NP (NPR p45)))))
                                          (N NF-E2)
                                          (NS proteins))))
                          (VBD increased)
                          (PP (P during)
                              (NP (NPR BA)
                                  (N treatment)))))
          (. .))
  (ID 207_nonfiction_GENIA-1999;99119105,7;NE))

( (IP-MAT (ADVP (ADV Moreover))
          (, ,)
          (NP-SBJ (ADJ antisense)
                  (NS oligodeoxynucleotides)
                  (RRC (VAG targeting)
                       (NP-OB1 (PRN (NP (CONJ either)
                                        (NP (NPR GATA-1))
                                        (CONJP (CONJ or)
                                               (NP (NPR p45)))))
                               (N NF-E2)
                               (NS proteins))))
          (VBD inhibited)
          (NP-OB1 (BIND *group*)
                  (Q both)
                  (NML (NP (N protein)
                           (N expression))
                       (CONJP (CONJ and)
                              (NP (ADJP (ADJ BA-induced))
                                  (N differentiation)))))
          (. .))
  (ID 208_nonfiction_GENIA-1999;99119105,8;NE))

( (IP-MAT (PP (P In)
              (NP (N contrast)))
          (, ,)
          (NP-SBJ (ADJP (ADJ BA-induced))
                  (N cell)
                  (N growth)
                  (N inhibition))
          (BED was)
          (NEG not)
          (VAN affected)
          (. .))
  (ID 209_nonfiction_GENIA-1999;99119105,9;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS results))
          (VBP provide)
          (NP-OB1 (D the)
                  (ADJ first)
                  (ADJ direct)
                  (N evidence)
                  (PP (P for)
                      (NP (D the)
                          (N requirement)
                          (PP (P of)
                              (NP (NP (NPR GATA-1))
                                  (CONJP (CONJ and)
                                         (NP (NPR NF-E2)))))
                          (PP (P in)
                              (NP (ADJP (ADJ BA-induced))
                                  (N differentiation)
                                  (N process))))))
          (. .))
  (ID 210_nonfiction_GENIA-1999;99119105,10;NE))

( (IP-MAT (NP-SBJ (D A)
                  (ADJ novel)
                  (ADJ growth-factor-dependent)
                  (ADJ myeloid)
                  (N cell)
                  (N line)
                  (RRC (VAN derived)
                       (PP (P from)
                           (NP (N mouse)
                               (N bone)
                               (N marrow)
                               (NS cells)))))
          (VBP contains)
          (NP-OB1 (NS progenitors)
                  (ADJP (ADJ endowed)
                        (PP (P with)
                            (NP (ADJ high)
                                (ADJ proliferative)
                                (N potential)))))
          (. .))
  (ID 211_nonfiction_GENIA-1999;99120322,1;NE))

( (IP-MAT (NP-SBJ (ADJ Constitutive)
                  (N expression)
                  (PP (P of)
                      (NP (ADJ human)
                          (ADJ colony-stimulating)
                          (NPR factor-1)
                          (N receptor)
                          (PRN (-LRB- -LRB-)
                               (N CSF-1R)
                               (-RRB- -RRB-)))))
          (VBP confers)
          (NP-OB1 (ADJ long-lasting)
                  (ADJP (ADJ CSF-1-dependent))
                  (N proliferation)
                  (PP (P to)
                      (NP (N mouse)
                          (ADJ myeloid)
                          (N cell)
                          (NS lines))))
          (. .))
  (ID 212_nonfiction_GENIA-1999;99120322,2;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBD developed)
          (NP-OB1 (NS mice)
                  (ADJP (ADJ transgenic)
                        (PP (P for)
                            (NP (ADJ human)
                                (N CSF-1R)))))
          (PP (P because)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (N mouse)
                                      (N CSF-1))
                              (MD can)
                              (NEG not)
                              (VB activate)
                              (NP-OB1 (ADJ human)
                                      (N CSF-1R)))))
          (CRD *)
          (. .))
  (ID 213_nonfiction_GENIA-1999;99120322,3;NE))

( (IP-MAT (ADVP-TMP (ADV Then))
          (NP-SBJ (N bone)
                  (N marrow)
                  (NS cells)
                  (PP (P from)
                      (NP (ADJ transgenic)
                          (NS mice))))
          (BED were)
          (VAN plated)
          (PP (P onto)
              (NP (N MS-5)
                  (ADJ stromal)
                  (NS cells)
                  (RRC (VAG expressing)
                       (NP-OB1 (D the)
                               (N membrane)
                               (N form)
                               (PP (P of)
                                   (NP (ADJ human)
                                       (N CSF-1)
                                       (PRN (-LRB- -LRB-)
                                            (NPR 2M-1)
                                            (NS cells)
                                            (-RRB- -RRB-))))))))
          (PP (P in)
              (NP (N order)
                  (IP-INF (TO to)
                          (VB combine)
                          (NP-OB1 (NP (D the)
                                      (ADJ hematopoietic)
                                      (N supporting)
                                      (NS properties)
                                      (PP (P of)
                                          (NP (ADJ stromal)
                                              (NS cells))))
                                  (CONJP (CONJ and)
                                         (NP (D the)
                                             (ADJ proliferative)
                                             (NS effects)
                                             (PP (P of)
                                                 (NP (N CSF-1)))))))))
          (. .))
  (ID 214_nonfiction_GENIA-1999;99120322,4;NE))

( (IP-MAT (ADVP (ADV Thus))
          (, ,)
          (NP-SBJ (PRO we))
          (BED were)
          (ADJP (ADJ able)
                (IP-INF (TO to)
                        (VB derive)
                        (NP-OB1 (D a)
                                (ADJ hematopoietic)
                                (N cell)
                                (N line)
                                (, ,)
                                (RRC (VBN called)
                                     (NP-OB1 (NPR 47.10)))
                                (, ,)
                                (CP-REL (WNP-1 0)
                                        (C that)
                                        (IP-SUB (NP-SBJ *T*-1)
                                                (VBD grew)
                                                (ADVP (ADV indefinitely))
                                                (PP (P under)
                                                    (NP (D these)
                                                        (NS conditions))))))))
          (, ,)
          (PP (P whereas)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (Q no)
                                      (N cell)
                                      (N line))
                              (MD could)
                              (BE be)
                              (VAN developed)
                              (PP (P from)
                                  (NP (ADJ nontransgenic)
                                      (NS mice))))))
          (. .))
  (ID 215_nonfiction_GENIA-1999;99120322,5;NE))

( (IP-MAT (NP-SBJ (N Proliferation)
                  (PP (P of)
                      (NP (NPR 47.10)
                          (NS cells))))
          (BEP is)
          (ADVP (ADV severely))
          (VAN affected)
          (PP (P by)
              (NP (ADJ neutralizing)
                  (ADJ anti-CSF-1R)
                  (ADJ monoclonal)
                  (NS antibodies)))
          (NP-LGS *by*)
          (. .))
  (ID 216_nonfiction_GENIA-1999;99120322,6;NE))

( (IP-MAT (NP-SBJ (ADJP (ADJP (ADJ Morphologic))
                        (CONJP (CONJ and)
                               (ADJP (ADJ cytofluorometry))))
                  (N analysis))
          (VBD established)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (QS most)
                                  (NPR 47.10)
                                  (NS cells))
                          (BEP are)
                          (NP-OB1 (ADJ immature)
                                  (ADJ myelomonocytic)
                                  (NS cells))))
          (. .))
  (ID 217_nonfiction_GENIA-1999;99120322,7;NE))

( (IP-MAT (ADJP-SPR (ADJ Consistent)
                    (PP (P with)
                        (NP (D this)
                            (N phenotype))))
          (, ,)
          (NP-SBJ (NP (D the)
                      (ADJ myeloid)
                      (N transcription)
                      (N factor)
                      (PRN (NPR PU.1)))
                  (, ,)
                  (CONJP (CONJ but)
                         (NEG not)
                         (NP (D the)
                             (ADJ erythroid)
                             (N transcription)
                             (N factor)
                             (PRN (NPR GATA-1)))))
          (, ,)
          (BEP is)
          (VAN expressed)
          (PP (P in)
              (NP (NPR 47.10)
                  (NS cells)))
          (. .))
  (ID 218_nonfiction_GENIA-1999;99120322,8;NE))

( (IP-MAT (NP-SBJ (D A)
                  (Q few)
                  (NPR 47.10)
                  (NS cells)
                  (NP-MSR (-LRB- -LRB-)
                          (NUM 3-5)
                          (N %)
                          (-RRB- -RRB-)))
          (DOP do)
          (NEG not)
          (VB express)
          (NP-OB1 (ADJP (ADJ lineage)
                        (ADJ specific))
                  (NS markers))
          (. ;))
  (ID 219_nonfiction_GENIA-1999;99120322,9;NE))

( (IP-MAT (NP-SBJ (PRO they))
          (VBP differentiate)
          (ADVP (ADV spontaneously))
          (PP (P to)
              (NP (ADJ lineage-positive)
                  (NS cells)))
          (PP (P after)
              (IP-PPL (VAG replating)
                      (PP (P on)
                          (NP (NPR 2M-1)
                              (NS cells)))))
          (CRD *)
          (. .))
  (ID 220_nonfiction_GENIA-1999;99120322,9;NE))

( (IP-MAT (PP (P In)
              (NP (N agar)
                  (NS cultures)))
          (, ,)
          (NP-SBJ (NPR 47.10)
                  (NS cells))
          (VBP form)
          (NP-OB1 (NP-TMP (NUMP (NUM 7-)
                                (CONJ and)
                                (NUM 14))
                          (N -day))
                  (NS colonies))
          (PP (P in)
              (NP (N response)
                  (PP (P to)
                      (NP (D a)
                          (N cocktail)
                          (PP (P of)
                              (NP (NP (N granulocyte/macrophage)
                                      (ADJ colony-stimulating)
                                      (N factor)
                                      (NP-MSR (-LRB- -LRB-)
                                              (NUM 2.5)
                                              (N ng/mL)
                                              (-RRB- -RRB-)))
                                  (, ,)
                                  (CONJP (NP (NPR interleukin-3)
                                             (NP-MSR (-LRB- -LRB-)
                                                     (NUM 1)
                                                     (N ng/mL)
                                                     (-RRB- -RRB-))))
                                  (, ,)
                                  (CONJP (CONJ and)
                                         (NP (N mouse)
                                             (N CSF-1)
                                             (NP-MSR (-LRB- -LRB-)
                                                     (NUM 10)
                                                     (N ng/mL)
                                                     (-RRB- -RRB-))))))))))
          (. .))
  (ID 221_nonfiction_GENIA-1999;99120322,10;NE))

( (IP-MAT (PP (P Under)
              (NP (D these)
                  (NS conditions)))
          (, ,)
          (NP-SBJ (NUMP (ADV about)
                        (NUM 0.5))
                  (N %)
                  (PP (P of)
                      (NP (NPR 47.10)
                          (NS cells))))
          (VBD formed)
          (NP-OB1 (ADJ large)
                  (NP-TMP (NUM 14)
                          (N -day))
                  (NS colonies)
                  (-LRB- -LRB-)
                  (CODE (FW >)
                        (FW 1)
                        (FW mm))
                  (-RRB- -RRB-)
                  (RRC (VAN composed)
                       (PP (P of)
                           (NP (ADJ mature)
                               (NML (NP (NS monocytes))
                                    (CONJP (CONJ and)
                                           (NS granulocytes)))))))
          (, ,)
          (IP-PPL (VAG reflecting)
                  (NP-OB1 (D the)
                          (N presence)
                          (PP (P of)
                              (NP (NS progenitors)
                                  (ADJP (ADJ endowed)
                                        (PP (P with)
                                            (NP (ADJ high)
                                                (ADJ proliferative)
                                                (N potential)
                                                (PRN (-LRB- -LRB-)
                                                     (NPR HPP-47.10)
                                                     (NS cells)
                                                     (-RRB- -RRB-)))))))))
          (. .))
  (ID 222_nonfiction_GENIA-1999;99120322,11;NE))

( (IP-MAT (PP (P In)
              (NP (N conclusion)))
          (, ,)
          (NP-SBJ (PRO we))
          (HVP have)
          (VBN characterized)
          (NP-OB1 (D a)
                  (ADJP (ADJ novel)
                        (ADJ continuous)
                        (ADJ myeloid))
                  (N cell)
                  (N line)
                  (RRC (VAG presenting)
                       (NP-OB1 (D a)
                               (ADJ hierarchical)
                               (N structure)
                               (ADJP (ADJ similar)
                                     (PP (P to)
                                         (NP (D that)
                                             (PP (P of)
                                                 (NP (D the)
                                                     (N bone)
                                                     (N marrow)
                                                     (N progenitor)
                                                     (N cell)
                                                     (N compartment)))))))))
          (. .))
  (ID 223_nonfiction_GENIA-1999;99120322,12;NE))

( (FRAG (NP (ADJ Imbalanced)
            (N expression)
            (PP (P of)
                (NP (D the)
                    (N glucocorticoid)
                    (N receptor)
                    (NS isoforms)
                    (PP (P in)
                        (NP (VBN cultured)
                            (NS lymphocytes)
                            (PP (P from)
                                (NP (D a)
                                    (N patient)
                                    (PP (P with)
                                        (NP (NP (ADJ systemic)
                                                (N glucocorticoid)
                                                (N resistance))
                                            (CONJP (CONJ and)
                                                   (NP (ADJ chronic)
                                                       (ADJ lymphocytic)
                                                       (N leukemia))))))))))))
        (. .))
  (ID 224_nonfiction_GENIA-1999;99120900,1;NE))

( (IP-MAT (NP-SBJ (D The)
                  (ADJ human)
                  (N glucocorticoid)
                  (N receptor)
                  (PRN (-LRB- -LRB-)
                       (N GR)
                       (-RRB- -RRB-)))
          (BEP is)
          (VAN expressed)
          (PP (P as)
              (NP (NUM two)
                  (ADJP (ADV alternatively)
                        (VBN spliced))
                  (NS isoforms)
                  (, ,)
                  (PRN (NP (NP (NPR GRalpha))
                           (CONJP (CONJ and)
                                  (NP (NPR GRbeta)))))))
          (. .))
  (ID 225_nonfiction_GENIA-1999;99120900,2;NE))

( (IP-MAT (PP (P Whereas)
              (CP-ADV (C 0)
                      (IP-SUB (NP-SBJ (NPR GRalpha))
                              (BEP is)
                              (NP-OB1 (D a)
                                      (ADJ hormone-activated)
                                      (N transcription)
                                      (N factor)))))
          (, ,)
          (NP-SBJ (NPR GRbeta))
          (VP (VP (DOP does)
                  (NEG not)
                  (VB bind)
                  (NP-OB1 (NS glucocorticoids)
                          (PRN (-LRB- -LRB-)
                               (NS GCs)
                               (-RRB- -RRB-))))
              (, ,)
              (CONJP (VP (BEP is)
                         (ADJP (ADV transcriptionally)
                               (ADJ inactive))))
              (, ,)
              (CONJP (CONJ and)
                     (VP (BEP is)
                         (NP-OB1 (D a)
                                 (ADJ potential)
                                 (N inhibitor)
                                 (PP (P of)
                                     (NP (VBN activated)
                                         (NPR GRalpha)))))))
          (. .))
  (ID 226_nonfiction_GENIA-1999;99120900,3;NE))

( (IP-MAT (NP-SBJ (ADJ Differential)
                  (N expression)
                  (PP (P of)
                      (NP (N GR)
                          (NS isoforms))))
          (MD may)
          (VB play)
          (NP-OB1 (D a)
                  (N role)
                  (PP (P in)
                      (NP (NP (VBN generalized))
                          (CONJP (CONJ or)
                                 (NP (ADJ tissue-specific)
                                     (N GC)
                                     (COPY *)
                                     (N resistance)
                                     (COPY *))))))
          (. .))
  (ID 227_nonfiction_GENIA-1999;99120900,4;NE))

( (IP-MAT (NP-SBJ (NS GCs))
          (VBP induce)
          (NP-OB1 (N apoptosis)
                  (PP (P in)
                      (NP (ADJ neoplastic)
                          (ADJ lymphoid)
                          (NS cells))))
          (. ;))
  (ID 228_nonfiction_GENIA-1999;99120900,5;NE))

( (IP-MAT (CONJ and)
          (, ,)
          (NP-SBJ (ADJ defective)
                  (N apoptosis))
          (BEP is)
          (VAN implicated)
          (PP (P in)
              (NP (D the)
                  (N genesis)
                  (PP (P of)
                      (NP (ADJ chronic)
                          (ADJ lymphocytic)
                          (N leukemia)
                          (PRN (-LRB- -LRB-)
                               (NPR CLL)
                               (-RRB- -RRB-))))))
          (. .))
  (ID 229_nonfiction_GENIA-1999;99120900,5;NE))

( (IP-MAT (NP-SBJ (PRO We))
          (VBD studied)
          (NP-OB1 (D a)
                  (N patient)
                  (PP (P with)
                      (NP (NP (ADJ generalized)
                              (N GC)
                              (N resistance))
                          (CONJP (CONJ and)
                                 (NP (NPR CLL))))))
          (. .))
  (ID 230_nonfiction_GENIA-1999;99120900,6;NE))

( (IP-MAT (NP-SBJ (N GR)
                  (N number)
                  (PP (P in)
                      (NP (NP-POS (D the)
                                  (N patient)
                                  (POS 's))
                          (VBN transformed)
                          (NS lymphocytes))))
          (BED was)
          (NP-OB1 (NUMP (ADV approximately)
                        (NUM one)
                        (NUM half))
                  (D that)
                  (PP (P of)
                      (NP (ADJ control)
                          (NS cells))))
          (PP (P with)
              (NP (D a)
                  (ADJP (ADV approximately)
                        (ADJ 10-fold))
                  (N reduction)
                  (PP (P in)
                      (NP (N binding)
                          (N affinity)
                          (PP (P for)
                              (NP (NPR dexamethasone)))))))
          (. .))
  (ID 231_nonfiction_GENIA-1999;99120900,7;NE))

( (IP-MAT (NP-SBJ (ADJP (FW In)
                        (FW vitro))
                  (N apoptosis)
                  (N induction)
                  (PP (P in)
                      (NP (NPR CLL)
                          (NS cells))))
          (BED was)
          (VAN delayed)
          (PP (PP (P in)
                  (NP (N response)
                      (PP (P to)
                          (NP (NS GCs)))))
              (, ,)
              (CONJP (CONJ but)
                     (PP (NEG not)
                         (P to)
                         (NP (ADJ other)
                             (N apoptosis)
                             (NS inducers)))))
          (. .))
  (ID 232_nonfiction_GENIA-1999;99120900,8;NE))

( (IP-MAT (NP-SBJ (N Sequencing)
                  (PP (P of)
                      (NP (NML (NP (D the)
                                   (N GR)
                                   (N cDNA))
                               (CONJP (CONJ and)
                                      (NP (N gene))))
                          (RRC (VAG including)
                               (NP-OB1 (NP (D the)
                                           (ADJ 2.3-kb)
                                           (N coding)
                                           (N region))
                                       (, ,)
                                       (CONJP (NP (D the)
                                                  (N intron/exon)
                                                  (NS junctions)))
                                       (, ,)
                                       (CONJP (NP (D the)
                                                  (ADJ known)
                                                  (ADJ 5'-regulatory)
                                                  (N region)))
                                       (, ,)
                                       (CONJP (CONJ and)
                                              (NP (NUMP (ADV approximately)
                                                        (NUM 300))
                                                  (N bp)
                                                  (PP (P of)
                                                      (NP (D the)
                                                          (N 3'-region))))))))))
          (VBD revealed)
          (NP-OB1 (Q no)
                  (NS alterations))
          (. .))
  (ID 233_nonfiction_GENIA-1999;99120900,9;NE))

( (IP-MAT (NP-SBJ (N Western)
                  (N blot)
                  (PP (P with)
                      (NP (D an)
                          (ADJ N-terminal)
                          (N antibody))))
          (VBD showed)
          (NP-OB1 (ADJ normal)
                  (NS levels)
                  (PP (P of)
                      (NP (ADJ immunoreactive)
                          (N GR))))
          (, ,))
  (ID 234_nonfiction_GENIA-1999;99120900,10;NE))

( (IP-MAT (CONJ but)
          (NP-SBJ (ADJ quantitative)
                  (N analysis)
                  (PP (P with)
                      (NP (ADJ isoform-specific)
                          (ADJ C-terminal)
                          (NS antibodies))))
          (VBD revealed)
          (NP-OB1 (NP (D a)
                      (ADJP (ADV markedly)
                            (VBN reduced))
                      (NPR GRalpha)
                      (N expression))
                  (, ,)
                  (CONJP (CONJ and)
                         (NP (ADJ high)
                             (NPR GRbeta)
                             (N expression))))
          (. .))
  (ID 235_nonfiction_GENIA-1999;99120900,10;NE))

( (IP-MAT (NP-SBJ (D These)
                  (NS findings))
          (VBP indicate)
          (CP-THT (C that)
                  (IP-SUB (NP-SBJ (ADJ imbalanced)
                                  (N expression)
                                  (PP (P of)
                                      (NP (D the)
                                          (N GR)
                                          (NS isoforms))))
                          (VP (VP (MD may)
                                  (BE be)
                                  (NP-OB1 (D a)
                                          (N mechanism)
                                          (PP (P of)
                                              (NP (N GC)
                                                  (N resistance)))))
                              (, ,)
                              (CONJP (CONJ and)
                                     (VP (MD may)
                                         (HV have)
                                         (NP-OB1 (NS implications)
                                                 (PP (P for)
                                                     (NP (N tumorigenesis))))
                                         (PP (P by)
                                             (IP-PPL (VAG enhancing)
                                                     (NP-OB1 (N cell)
                                                             (N survival))))
                                         (CRD *))))))
          (. .))
  (ID 236_nonfiction_GENIA-1999;99120900,11;NE))

( (FRAG (NP (N Copyright)
            (NPR 1999))
        (NP (NPR Academic)
            (NPR Press))
        (. .))
  (ID 237_nonfiction_GENIA-1999;99120900,12;NE))
